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ABSTRACT
Chronic obstructive pulmonary disease (COPD) was found to be the fourth leading cause of
death in 2004, but current treatments can only relieve the symptoms and improve the quality of life
for the patients. Glucocorticoids have been broadly applied in other inflammatory conditions with
promising therapeutic effects, but performed poorly in COPD. The phenomenon called
glucocorticoid resistance is responsible for glucocorticoid insensitivity in COPD. Researchers have
proven that elevated oxidative stress in the lung of a COPD patient is one of the main causes of
blocking the function of glucocorticoids. We hypothesize that reducing the oxidative stress in the
lung can restore the therapeutic effect of glucocorticoids in COPD. Thus, simultaneous
administration of antioxidant and glucocorticoid drugs could be a promising approach to treat this
condition.

In order to achieve this goal, liposomes loaded with both glucocorticoids and antioxidants
were developed and characterized. First, several types of nano-carrier candidates were prepared
and tested, and based on the comparative study liposomes were selected as the nano-carrier system
of choice for further experiments.

In order to quantitatively determine the relationship between the targeting efficacy and the
amount of the targeting antibody immobilized on the surface of the liposomes, surface plasmon
resonance (SPR) was performed. It was shown that initial increase of the affinity upon the increase
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of the targeting antibody surface density was followed by the saturation of binding affinity at
certain antibody surface density. This saturation surface density was independent regardless of the
size of the liposomes or even the type of the targeting antibody and its ligand. This saturation point
was important in optimization of the targeting efficacy of the liposomes coated with the targeting
antibody.

In order to address the glucocorticoid resistance induced by the oxidative stress, and test the
hypothesis of the synergistic action of the antioxidant and glucocorticoid drugs, a cell culture
model was developed. Exogenous ROS were proven to be necessary in this model. The synergistic
effect of the co-delivery of the two drugs was demonstrated by measuring pro-inflammatory
response. Analysis of the gene expression of several important biomarkers showed that the
mechanism of action involved restoration of the expression of histone deacetylases 2 (HDAC2) in
the presence of the antioxidant. Later, this cell culture model also proved the increased drug
availability in the case of targeted liposome-based delivery.

Overall, this targeted delivery system loaded both antioxidant and glucocorticoid drugs
provided another approach to address the problem of treatment of COPD.
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CHAPTER 1
INTRODUCTION
The goal of this study was to design nano-carriers loaded simultaneously with both
antioxidant and anti-inflammatory drugs. Because the anti-inflammatory effect of glucocorticoids
is hampered by oxidative stress, targeted delivery is required to achieve specific binding and
prolonged residence time in the pulmonary system.

Chapter Two presents an overview of the background and clinical significance of this study. It
includes a discussion of COPD pathogenesis, the structural alteration of a lung with this condition,
its current treatments, and the direction of the research.

Chapter Three divides this work into 3 specific aims. First, this study focused on the
formation and selection of the ideal nano-sized vehicle. In addition, surface plasmon resonance
(SPR) was used to quantitatively investigate the targeting efficacy derived from the targeting
antibody immobilized onto the nano-carriers. Finally, an in vitro model was used to investigate the
anti-inflammatory effect of the co-delivery system.

Chapter Four discusses the various types of nano-carriers loaded with either antioxidants or
glucocorticoids prepared using different mechanisms. Liposomes, double-emulsion poly
(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs), and polylactic acid (PLA) NPs were
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initially chosen as candidates. The properties of those nano-carriers, including size, zeta-potential,
drug loading capability, and storage stability, were determined. Their stability was determined
based on lyophilization with cryoprotectors and long-term storage at room temperature. Based on
these analyses, liposomes were selected as the nano-sized vehicles for this study. The drug release
profile of glucocorticoid was investigated through a dialysis-based technique with bovine serum
albumin facilitating the release.

Chapter Five presents the analysis of the targeting efficacy derived from the targeting
antibodies immobilized on the surface of the liposomes as determined by SPR in comparison to the
conventional cell binding method. SPR is a more kinetic and quantitative technique for determining
targeting efficacy than the cell binding method. This chapter covers the analysis of liposomes with
various targeting antibody surface densities, sizes of liposomes, and types of the targeting
antibodies. A pilot model of a secondary antibody targeting to its coupled primary antibody was
conducted before testing the real targeting antibody. The avidity effect derived from the multiple
binding sites on the surface of the liposome is also reported in this chapter; in addition, the
saturation of the increasing trend of targeting efficacy derived from the avidity effect is discussed,
an analysis essential for the further optimization of targeted liposomes.

The sixth chapter concentrates on the protective effect achieved from the liposome system
using an in vitro model with glucocorticoid resistance. This model was developed by challenging
2

A549 cells with lipopolysaccharide (LPS), with an exogenous oxidant being used to achieve
glucocorticoid resistance. To determine the cell response to the challenges and drugs,
enzyme-linked immunosorbent assay (ELISA) was used to measure the concentration of released
interleukin 8 (IL-8). In addition, quantitative SPR was used to analyze the gene expression of
several important biomarkers relative to inflammatory response. In this chapter, the protective
effect from the free drugs mixture and drug-loaded liposomes is presented.

Overall conclusions of the studies are included in Chapter Seven. First, targeted drug delivery
devices carrying both antioxidant (SOD/SOD mimetic) and glucocorticoid (DEX) drugs were
prepared and characterized. Second, the effect of the density of the targeting antibody on the
affinity of nanoscale drug carriers was investigated, and optimal antibody density was determined.
Third, the synergistic effect between glucocorticoid and antioxidant drugs was demonstrated in
the A549 cell culture model.
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CHAPTER 2
LITERATURE REVIEW
Chronic obstructive pulmonary disease (COPD) is a respiratory condition that involves
chronic inflammatory of the lung tissue, usually caused by smoking. The term “COPD” was
introduced in 2002 as a combined description of the two terms, “chronic bronchitis” and
“emphysema” that were used previously [1]. According to the World Health Organization (WHO)
assessment, COPD was the fourth leading cause of death worldwide in 2008. The incidence of
COPD is projected to increase by more than 30% over the next 10 years, and COPD is expected to
become the third leading cause of death by 2028. In 2013, COPD affected more than 24 million
Americans, and has already become the third leading cause of death in the US. Disability caused by
COPD significantly adds to the burden of this condition. At present, there is no practical cure as
most of the current treatments are limited to relieving the symptoms, slowing its progress, and
improving the quality of life for the patients.

2.1. Pathology of Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease (COPD) is a disease induced by smoking, and its
development and progress are mainly attributed to the increased oxidative stress from tobacco
smoking. COPD can be categorized into three different pathological mechanisms which all cause
4

air trapping and lung hyperinflation [2]:



Chronic bronchitis is defined by cough and sputum, which are shown to be relative with
airway mucosal surface, the submucosal glands, and gland ducts, particularly in the small
bronchi between 2 and 4mm in diameter. This inflammatory results in an increase in airway
smooth muscle, a generalized increase in the connective tissue in the airway wall,
degenerative changes in the airway cartilage and a shift in the epithelial cell type.



Emphysema has been defined as “abnormal permanent enlargement of airspaces distal to
terminal bronchioles, accompanied by destruction of the walls without obvious fibrosis”.
Emphysema, caused by both the lack of elastic support in the alveolar attachment which
disables the close of the small airways, and the decrease of intra-luminal pressure from loss
of elastic recoil.



Airways obstruction in COPD is in the smaller conducting airways that include bronchi and
bronchioles less than 2 mm diameter, caused by the destruction of alveolar support of the
peripheral airways, the loss of elastic recoil in the parenchyma supporting the airways,
structural narrowing of the airway lumen by the inflammatory remodeling process.

All these mechanisms will lead to air trapping and lung hyperinflation, resulting in dyspnea.
FEV1 is the volume of air that can forcibly be blown out in one second, which is an important index
to assess the lung function. For COPD patients, declined FEV1, or FEV1 over FVC (the volume of
5

air that can forcibly be blown out after full inspiration) is found, and these are the indicators to
monitor the progression of COPD [3].

There are two direct consequences of reactive oxygen species (ROS) from tobacco use:
epithelial injury and inflammatory response. Epithelial injury increases permeability of the
respiratory epithelium right after the exposure to smoke, dramatically increasing the risk of
infection, which plays a key role in COPD exacerbation. Up to two-thirds of exacerbations are
related to microbial infection. Recent studies hypothesize the relationship between the infection
and the risk of development of COPD. It has also been found that inflammatory is the essential
mechanism of development of COPD [4].

2.1.1. Epithelial cells and macrophages

Oxidative stress is present whenever inflammatory exists. Studies have proven that for
oxidative stress activates or enhance the inflammatory in COPD. Interleukin 8 (IL-8), an
inflammatory mediator, which is usually indicative of the extent of inflammatory, is found to be
released from epithelial cells upon increasing oxidative insult. Epithelial cells from COPD patients
were found to release more IL-8 than those of healthy persons. 8-isoprostance and 4-HNE,
produced by lipid peroxidation, can also act as signaling mediators to activate the release of
inflammatory mediators such as IL-8 and Transforming growth factor beta (TGFβ). Studies
hypothesized that the mechanism of smoke-induced inflammatory lies on a more fundamental level.
6

Redox-sensitive transcription factors have recently been shown to be increased by oxidative stress,
such as (nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and activator
protein 1 (AP-1) [5]. NF-κB was found to play a key role in airway inflammatory, because many
inflammatory mediators are regulated by NF-κB. It is present in cytosol as an inactive form,
which is inhibited by protein (Inhibitor of κB) IκB [6]. Oxidants can result in activation of IκB
kinase, cleaving IκB from NF-κB and releasing NF-κB. Studies from both macrophages and
airway epithelial cells demonstrated that the release of inflammatory mediators, such as IL-8,
IL-1, and NO correlate with the concentration of oxidants, which are also accompanied by
enhanced nuclear binding and activation of NF-κB

Along with epithelial cells, alveolar macrophages play a critical role in the pathophysiology of
COPD [7]. Normal macrophages are exposes to inhaled particulates, but produce low level of
cytokines and are poorly phagocytic. This is because the cell-cell interaction induces TGF-β
dependent expression of αvβ6 in alveolar epithelial cells, which suppresses both of the production
of cytokines and phagocytosis [8]. Macrophages are activated by smoking due to release of
inflammatory mediators.

2.1.2. Cytokines

Initially, CXC (proteins with two N-terminal cysteines which are separated by on an amino
acid) and CC (proteins that have two adjacent cysteines) chemokines are immediately produced
7

after activation by alveolar macrophages. IL-8, common CXC cytokines as mentioned previously
are important in the inflammatory network, and can respond to several stimuli, including smoke
extract which contains a high concentration of reactive oxygen species (ROS). Alveolar
macrophages from COPD patients were found to release much more IL-8 than in normal smokers
and non-smokers. Along with other CXC chemokine including GCP-2/CXCL-6, GROα/CXCL1,
GROβ/CXCL2, GROγ/CXCL3 and NAP-2/CXCL7, IL8 has been found to be the major
polymorphnuclear neutrophils (PMN) chemoattractant [9, 10]. Cytokines stimulate neutrophils via
two different receptors namely CXCR1 and CXCR2. Enhanced levels of all of these chemokines
are found in either COPD patients’ bronchoalveolar lavage (BAL) fluid or sputum compared with
normal controls. Reversely, the neutrophils themselves may be a major source of CXCL 8 [11]. In
addition, another group of chemokines also can be released from alveolar macrophages, including
CXCL10 (IP-10), CXCL11 (I-TAC) and CXCL9 (Mig), which are found to be chemotactic for
CD8+ TC1 and CD4+ Th1 cells via interaction with the CXCR3 receptor expressed on these cells
[9]. Similarly, CXCL9, CXCL10, and CXCL11 are found to be increased in COPD. Moreover,
since the CXCR3 ligands CXCL9, CXCL10, and CXCL11 are all induced by interferon gamma
(IFN-γ), and (classification determinant) CD8+ T-cell are themselves a source of IFN-γ, there is a
high probability for further positive feedback. Another family of cytokines, which plays an
important role in COPD is CC chemokines. Compared to CXC chemokines, CC cytokines induce
the migration of monocytes, NK cells, dendritic cells, eosinophils and basophils, which all play
8

roles in attracting T-cells [12-14].

2.1.3. Lipid mediators

Besides cytokines, which are proteins, some bioactive lipid mediators are also important in
the inflammatory response. These include leukotrienes (LTs), lipoxins (LX), prostaglandins (PG),
and thromboxane (Tx). These can be generated by alveolar macrophages and other human lung
cells, like mast cells, T-helper cells and other leukocytes, in inflammatory. Macrophages produce a
substantial excess of leukotriene B4 (LTB4) with leukotriene C4 (LTC4) after stimulation. Also, it
was found that in patients with COPD, LTB4 concentration was increased. The role of LTs in the
pathophysiology of COPD is uncertain. LTB4 was found to be a potent neutrophil chemoattractant,
and cysteinyl(cys)-LTs which cause bronchoconstriction and have found having proinflammatory
effects, since it can promote the synthesis of tumor necrosis factor alpha (TNF-α), IL-8, GROα,
CXCL1, and IL-6 by macrophage. prostaglandins D2 (PGD2) is known as another essential lipid
mediator. It is also known to generate chemotaxis of eosinophils and TH2 lymphocytes, and
stimulate cytokine production by TH2 cells. Moreover, both PGD2 and PGF2α may play a role as a
mediator of bronchoconstriction and airway hyperresponsiveness [15] [16].

2.1.4. Proteinases

Alveolar macrophages also secrete elastolytic enzymes. There are many proteolytic enzymes
released in the lung, not only by macrophages, but neutrophils are also capable of degrading elastin.
9

They produce serine proteases, cysteine proteinase, and matrix metalloproteinases (MMPs) [17].
Serine proteases are characterized by a catalytic triad (His,Asp, and Ser) which forms a
charge-relay system transferring of electrons from the carboxyl group of Asp to the oxygen of Ser,
which later becomes a powerful nucleophile and is able to attack the carbonyl carbon atom in
peptides. Neutrophil elastase (NE), cathepsin G, and proteinase 3 are common serine proteinase in
COPD, which are mainly coming from neutrophils. On the other hand, another group of proteolytic
enzymes, cysteine proteinases utilizes a sulfhydryl group of Cys as the nucleophile and is mainly
produced by alveolar macrophages in COPD. Besides, MMPs is another group of proteolytic
enzymes which have been implicated in COPD. Among them, MMP-2, MMP-9, and MMP-12 are
well studied [18]. It has been proven that all these bioactive molecules are regulated by NF-κB,
which is already proven to be activated by ROS in the lung. It has been found that these
elastolytic proteins, especially MMP-12 and neutrophil NE, contribute to lung destruction via the
elastin degradation, which is related to emphysema. By genetic engineering, MMP-12-/- and
neutrophil NE-/- mice were significantly protected from cigarette induced emphysema [19]. Thus,
Shapiro, S.D., et al. demonstrated a direct role for neutrophil elastase in emphysema and
emphasized the interdependence of the proteinase and inflammatory cells in response to smoking.
The degradation of elastin would introduce positive feedback to COPD, since the fragment of
elastin has been proven to be an auto-immune target.

10

2.1.5. ROS signaling in COPD

Environmental and inflammatory cell-derived ROS have been implicated in the activation of
transcription factors such as NF-κB and AP-1, and in the signal transduction and gene expression
involved in cellular pro-inflammatory actions. NF- κB has been proven to switch on multiple
inflammatory genes resulting in amplification of the inflammatory response [20]. The pathway of
NF- κB activation is not totally clear, but there are several redox-sensitive steps in the activation
pathway as mentioned above. In inflammatory, neutrophils and other inflammatory cells are
attracted into the lungs. These cells can generate ROS via the NADPH oxidase system. Moreover,
cigarette smoking is associated with an increase in myeloperoxidase (MPO) content in
neutrophils, and MPO activity is found to be negatively correlated with FEV1 in patients with
COPD. Also, increased amount of ROS including O2•- and H2O2 is found from smokers BAL
fluid. Thus, the ROS from cigarettes can raise the inflammatory reaction in respiratory space via
NF-κB and other signal transduction. Later, inflammatory cells can continuously generate
secondary ROS in the lung providing a positive feedback for ROS in COPD.

2.1.6. Growth factors

The tissue repair process is supposed to return the tissue function back to normal, but in
chronic tissue injury, like smoking, it appears that the repair process loses many control
mechanisms and later the remodeling of tissue alters the normal function. Remodeling at the
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alveolar level and fibrosis of the small airway are commonly found in COPD [4]. Many growth
factors from macrophages, epithelial cells, and other inflammatory cells can influence the
phenotype of the tissue cells and induce tissue remodeling. Many cytokines and growth factors
can be found at the site of tissue remodeling, but it is hard to determine the causal relationship
between them. It is believed that TGF-β plays an important role in peribronchiolar fibrosis.
Among 5 isoforms, TGF-β1, is most abundant and well characterized. TGF-β can stimulate
extracellular matrix (ECM) production including collagen and fibronectin and reduce the
degradation of collagen [21]. It also can induce the transformation of fibroblasts into
myofibroblasts, which are contractile cells and produce more matrix proteins. However, matrix
protein production is potentially a pathogenic process for fibrosis. TGF-β can be up-regulated by,
IL-1, GM-CSF, PDGF, and TGF-β itself and it can also induce the secretion of FGE, PDGF, and
CTGF.

Other growth factors also play important roles. For example, VEGF, which is a major
physiological regulator of vascular growth, can cause hypoxic pulmonary vasoconstriction in
COPD. Cigarette smoking activates TGF-α and then activates EGFR, resulting in the increase of
mucus secretion.

2.1.7. Other inflammatory cells in COPD

Increased numbers of neutrophils are found in COPD patients’ BAL and sputum. The
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recruitment of neutrophils is induced by many kinds of chemokines, including LTB4, CXCL8,
CXCL1 and CXCL5, which can be produced by alveolar macrophages, T-cells and epithelial
cells, and even the neutrophils themselves, especially in the case of CXCL8. Besides the
production of CXCL8, another obvious role of neutrophils is secretion of proteinases, which
mainly are serine proteinase and matrix metalloproteinases.

Dendritic cells play a central role in the innate and adaptive immune response [22]. In
COPD, they have been found to activate many kinds of cells including macrophages, neutrophils,
T and B lymphocytes. T-lymphocytes are found to increase in the airway of patients with COPD.
CD8+ cells (cytotoxic T cells) and CD4+ cells (mature helper T cells) are important in the
inflammatory response in the airways. In general, the expression of CXCL10 attracts these T cells,
which preferentially express CXCR3. The chronic colonization by bacterial and viral pathogens
is one possible reason for T cell accumulation. Besides, injury directly from smoking or from
inflammatory may uncover the antoantigens which are sequestered in intact tissue, the role of T
cells in COPD is not clear, but it can definitely produce the damage in the lung. The T cells
release perforins, granzyme B, and TNF-α, which can cause cytolysis and apoptosis of alveolar
epithelial cells. These damages will release more antigenic material. Moreover, CD8+ cells can
release cytokines that can enhance the inflammatory reaction. T-helper cells are the main source
of Interferon-gamma (IFN-γ), which is a cytokine critical for immunity [9].
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Eosinophil infiltration is found in COPD, especially in exacerbation of COPD. Since the
exacerbation may relate to viral infection, the eosinophils have a role in antiviral defense.

2.1.8. Summary

As factors illustrated above, all the cytokines, inflammatory cells, lipid mediators, ROS, and
growth factors form a general network of COPD pathogenesis (Figure 1) [23, 24]. Each factor is
induced by others and also can cause the activation of many other factors. Actually, the causal
relationship cannot be totally clarified. Many positive feedback mechanisms are involved in the
process of COPD development, which is supposed to exaggerate the situation. Generally, irritants
(mainly ROS) from smoke activate epithelial cells and macrophages to release chemotactic
factors that attract inflammatory cells to the lungs. Some of the cytokines attract monocytes, and
some attract neutrophils and monocytes, and others attract T-cells. All these inflammatory cells
together with macrophages and epithelial cells can release protease which can degrade elastin
leading to emphysema. The growth factors from epithelial cells and macrophages stimulate
fibroblast proliferation resulting in fibrosis in small airways. Growth factors can also induce
mucus hypersecretion. The growth factors, cytokines, and ROS can further amplify inflammatory
via positive feedbacks loops.
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Figure 1. Inflammatory cells and mediators involved in COPD. Inhaled cigarette smoke
and other irritants activate epithelial cells and macrophages to release several
chemotactic factors that attract inflammatory cells to the lungs.

2.2. Current pharmacotherapy of COPD
Due to the increasing mortality from COPD, there is a pressing need for effective drug
treatment. Some treatments are non-drug therapies including dietary, smoke cessation, long-term
oxygen therapy, mechanical bronchial ventilation, and certain surgical procedures. On the other
hand, pharmaceutical therapy is also a reliable method of COPD treatment. Many studies have
been done on a variety of potential therapeutic drugs, including bronchodilators, mediator
antagonists, chemokine receptor antagonists, anti-inflammatory reagent, and anti-oxidant drugs
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(Table 1) [25] .

Table 1. Potential therapeutic options in smokers with COPD
Drug class

Examples
Nicotine Replacement Therapy

Smoking Cessation

Buproprion
Varenicline
Fluticasone/Salmeterol

ICS, ICS/LABA combination

Budesonide/Formoterol
Mometasone/Formoterol

Long-acting Anticholinergics

Tiotropium
Montelukast

Leukotriene Modifiers
Zileuton
Theophylline
HDAC2 Enhancers

Peroxynitrite Scavenger Drugs
Macrolides

Peroxisome Proliferator-Activated
Rosiglitazone
Receptor Agonists
PDE4 Inhibitors
Other Anti-Inflammatory Agents

P38 MAPK inhibitor
TNF – α inhibitors

* ICS = Inhaled corticosteroids, LABA = Long-acting beta2-agonists, HDAC2 = Histone
deacetylase 2.
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2.2.1. Corticosteroids

Corticosteroids also known as glucocorticosteroids, are a traditional anti-inflammatory drug
and are effective in controlling inflammatory conditions such as asthma and arthritis [26-32]. The
inflammatory signals like TNF-α activate NF-κB indirectly inducing acetylation of histones by
histone acetyltransferase (HAT), increasing the expression of genes encoding inflammatory
proteins [27]. Corticosteroids can reverse this histone acetylation by activating histone
deacetylase-2 (HDAC2). HDAC is family of enzyme which counteracts the function of HAT,
which silence the expression of genes and HDAC2 was proven to play a significant role in
silencing inflammatory genes.

Even inhaled corticosteroids have been proven effective in asthma treatment, and also been
applied on COPD treatment for a long time. Its therapeutic effect became more controversial
recently. One of the main concerns about this controversy is the concept of glucocorticoid
resistance in the COPD patients. In the situation of COPD, relatively higher dosage of inhaled
corticosteroid induced limited efficacy and significant adverse effect [33]. Many studies proposed
diverse mechanisms of his phenomenon, and one popular theory is that the high exogenous ROS
from tobacco smoking can either decrease the production of HDAC2 or reduce its activity [27],
significantly compromised the suppression of inflammatory from corticosteroid.

17

2.2.2. Beta2-agonists

β2-agonists are traditional bronchodilators, which have been used for pulmonary diseases for a
long time. Initially targeting asthma. β2-agonists can bind to the β2-adreniceptor presented on
vascular smooth muscle cells leading to the relaxation of the airway smooth muscle [34]. The
β2-adreniceptor is found to be a G-protein coupled receptor, whose α-subunits can get released by a
β2-agonist binding. This subunit can stimulate adenylyl cyclase, which produce cyclic AMP
(cAMP) from ATP. cAMP, known as an important secondary messenger of intracellular signal
transduction, can activate protein kinase A. Protein kinase A later phosphorylates key targets which
can change the phenotype of airway smooth muscle cells and relax the airway smooth muscle.
β2-agonists can bind to 3 α-helices from the transmembrane domain of receptors. However, some
long-acting agonists like salbutaline and terbutaline can prolong the duration of action due to an
additional lipophilic tail binding. Moreover, the substitution and reposition of the hydroxyl group
of the catecholamine structure of β2-agonists are found to decrease therapeutic ability but increase
the resistance to catechol-O-methyltransferase (COMT), such as salbutamol and terbutaline. A
significant volume of published evidence supports the role of β2-adreniceptor in the treatment of
COPD [35]. Physiologically, β2-agonists dilate the airways and reduce the air trapping and
wheezing to improve lung function and improve the exercise tolerance, and thus improving the
quality of life.
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Later, some clinical benefit was determined from the combination of β2-agonists with other
potential reagents including antimuscarinic agents. Meanwhile, the combination of long acting
β2-agonists and corticosteroids has shown benefits in clinical studies. Many evidences
demonstrated that these two agents have a synergy when combined. Cave et al. summarized that
corticosteroids can increase the β-receptor density, and enhance Gαx expression. Reversely the
β2-agonists can recruit histone deaceylases to the promotor regions of target pro-inflammatiory
genes to repress transcription [36]. However, this combination also got compromised by the smoke
induced HDAC2 reduction [37].

β2-agonists are central in the symptomatic management of asthma and COPD. However, with
its side effects and limited improvement of the lung function this treatment does not address the
underlying mechanisms of COPD [38]. After long-term and high-dosage exposure some side
effects become obvious and severe. Some studies indicate that β2-agonists demonstrate
pro-inflammatory effects [39, 40]. Salpeter et al. claimed that regularly inhaled beta-agonists
increased the risk of respiratory death by more than two-fold, compared with a placebo [41].

Other bronchodilators are also applied to reduce COPD. Tiotropium bromide is one of
anticholinergic bronchodilators, which is a muscarinic receptor antagonist that cuts off the
cholinergic reflex bronchoconstriction. Moreover, some other bronchodilators such as Viozan are
currently in clinical development. Viozan is a dual agonist of both β2-adrenergic and dopamine D2
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receptor, which can inhibit cough and reflex mucus secretion.

2.3. Source and mechanisms of reactive oxygen species
As discussed above, ROS are strongly involved in pathophysiology of COPD. Furthermore,
the most straightforward treatment option by glucocorticoids is also strongly affected and
eventually rendered inefficient by ROS. Therefore, it is important to understand details of
production and mechanism of action of ROS, which is discussed in the following section”.

2.3.1. Endogenous generation of ROS

ROS (Reactive oxygen species) are oxygen compound derived from metabolism, which
includes superoxide (O2·-), hydrogen peroxide (H2O2), hydroxyl radical (OH·), peroxyl radical
(ROO·), alkoxyl radical (RO·), ozone (O3), and singlet oxygen (1O2) [42-45] (Figure 2). The
formation of singlet oxygen can later result in the sequential reduction of superoxide, hydrogen
peroxide, and hydroxyl radical. However, other research claim that O2·- is known as the precursor
of most ROS in the cell, and this radical processes the most high oxidizability [45]. The cellular
sources of ROS are mitochondria, cytochrome P450 family protein, xanthine oxidoreductase (XO),
cyclycooxygenases (COX), lipoxygenases, and the NADPH oxidase (Nox) family [46].
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Figure 2. Generation of different ROS by energy transfer or sequential univalent
reduction of ground states triplet oxygen.

Under normal metabolism condition, the main source of O2·- is the mitochondrial electron
transports chain which is the major source of ATP in the body. About 1 to 3 percentage of O2 can be
reduced in mitochondria into O2·- by the electrons leaked from the chain. This superoxide can be
produced by both complex I (NADH dehydrogenase) and complex III (ubiquinone-cytochrome c
reductase) of that electron chain. It also has been detected that O2·- from complex III is
extra-mitochondrially release into cytosol directly.

In ischemia reperfusion, xanthine oxidase in cytosol would transfer electrons abnormally to
O2, rather than to NAD+ [47]. Moreover, in the inflammatory, NADPH oxidase of phagocytic cells
becomes the major source of O2·- in the tissue; these superoxide ions are important to kill any
invading microorganisms. In addition, certain enzymes produce O2·- as part of their normal
function. For example cytochrome, nitric oxide synthases, and cyclooxygenase can all produce O2·as a side product. Furthermore, some bio-active molecules, such as glyceraldehyde, FMNH2, and
21

some thiol containing molecules (e.g., cysteine) can produce O2·- through auto-oxidation[45].

2.3.2. Oxidative damage

Traditionally, researches are focused on the oxidative damage induced by ROS through lipid
peroxidation on membranes, DNA damage, and protein oxidation [48]. The most important of
these mechanisms is the oxidation of cellular membrane by the process of lipid peroxidation. ROS
like OH·, HO2·-, and OONO- can attack a methylene group binding a proton and leaving a carbon
radical in the lipid. This initial carbon radical can then attack other methylene groups in lipid
molecules, leading to a chain reaction, which can alter the integrity of lipid molecules in cell
membrane [49]. ROS can also result in DNA strand breaks. The Fenton reaction, which includes
iron or copper ions, can help to generate highly toxic OH· and then alter the transcriptional and
translational process of DNA [50]. In addition, ROS can attack certain amino acids in proteins,
some examples including reactions with tyrosine to produce 3-nitrotyrosin, or reactions with
histidine, arginine, lysine and proline to generate a carbonyl group. These oxidation reactions can
affect protein’s affinity to its receptor or enzymatic activity.

2.3.3. Redox homeostasis

Thus, the balance between ROS and antioxidant and the steady concentration of ROS is based
on the balance between their production removal rates, which is currently referred to as redox
hemostasis. Redox state, which refers to a concentration ratio of a redox pair, e.g. Glutathione
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(GSSG/2GSH) or ascorbate (Asc•-/AcsH-), describes the general condition of the cell. According to
redox hemostasis, the redox state is maintained within a relatively narrow range under normal
conditions. The redox homeostasis is attributed to the buffering capacity derived from GSH and
thioredoxin (TRX). Glutathione acts as the major cellular redox buffer and is a representative
indicator for the redox status of the cell. Under increased oxidative condition, GSSG concentration
also increases. Thus increased GSSG concentration can interfere with the function of many critical
proteins through the formation of disulfides from thiol groups. Examples of such proteins include
receptors, protein kinases and some transcription factors. Besides GSH and TRX, many kinds of
low molecular weight antioxidants can be significantly involved in ROS scavenging activities.
This mechanism is mainly related to free amino acids, peptides, and proteins. It was found that
oxidized proteins are much more vulnerable to proteolytic degradation [51].

2.3.4. Signaling of ROS

Recent studies showed that besides causing physical damage to biomolecules ROS also have a
role as regulators of metabolic processes [45]. Signal transduction is a process enabling
information to be transmitted from the outside of a cell to various functional elements inside the
cell. Signal transduction is triggered by extracellular signals, such as hormones, growth factors,
cytokines and neurotransmitters. Signals are designed to influence transcription machinery that is
responsible for expression of a certain gene, and signals are normally transmitted to the cell
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nucleus by a class of proteins called transcription factors. ROS were found to play a major
physiological role in several aspects of intracellular signaling and regulation.

Growth factors, cytokines, or other ligands can induce ROS generation in non-phagocytic
cells through the specific binding to membrane receptors. This signal transduction can often be
enhanced by the ROS production or by a pro-oxidative shift of the intracellular thiol/disulfide
redox state, which generates a kind of positive feedback. More specifically, it was found that nerve
growth factor (NGF), epidermal growth factor (EGF), and Platelet Derivation Growth Factor
(PDGF) can induce intra-cellular ROS through the signaling protein Rac1, which is a specific type
of G-protein [52]. Also, growth factors’ functions are inhibited by hydrogen peroxide removal.
There is a strong possibility that the redox dependency of the signal transduction process may
facilitate synergistic interactions between different types of membrane receptors. For example,
angiotensin II type I receptor, which is a G-protein-coupled receptor, was found to induce
responses by ROS that are normally activated by tyrosine kinase-linked receptor.

Protein tyrosine phosphatases (PTP) counteract the effect of protein tyrosine kinases (PTK),
which

can

dephosphorylate

all

tyrosine

residues

immediately

after

ligand-induced

autophosphorylation and reset PTK receptor back to the normal situation. However, this
phosphatase is inhibited by high levels of ROS by cysteine oxidation in cell, and thus ROS slows
down the dephosphorylation and directly triggers PTK [53]. Then, increased level of tyrosine
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phosphorylation co-regulates PTKs along with its ligands. For example, insulin receptor has higher
sensitivity to insulin only with certain concentration of ROS. The activity of several protein
tyrosine kinases such as LCK, Fyn, Syk, and ZAP70 was found to be regulated by ROS [31].

Similar to PTK, serine/threonine kinases can also be regulated by ROS concentration. Among
serine/threonine kinases, PKC is significant to transcription and cell cycle control. This PKC was
proven to be activated by hydrogen peroxide via cysteine-region domain. Akt, a serine/threonine
kinase, is involved in PI3K and can be activated by phosphorylation. This mechanism has the effect
on inhibition of an apoptosis pathway. Recently some studies proved that ROS participate in
activation of this mechanism [54].

Mitogen-activated protein kinases (MAPK) signaling cascades are regulated by
phosphorylation and dephosphorylation on serine/ threonine residues and are activated by the
either receptor tyrosine kinases, protein tyrosine kinases, receptors of cytokines or heterotrimeric G
protein-coupled receptors. Different species of MAPK, including JNK and p38 are strongly
activated by ROS or by a mild oxidative shift in the intracellular thiol/disulfide redox state. Two
other enzymes, signal-regulated kinase 1 (ERK) and ERK-2 were found to be activated in vascular
smooth muscle cells by superoxide [55]. Furthermore, studies on the up-regulation of MAPKs by
H2O2 have demonstrated that activation is both type and stimulus specific. For example,
endogenous H2O2 from respiratory burst can induce ERK but not p38 kinase activity, while
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exogenous H2O2 activates p38 kinase but not ERK in rat alveolar macrophages [46].

The most significant effect of ROS on signaling pathway is thought to be on the MAPK
pathway since it is involved in expression of the genes that control the immune system,
proliferation and apoptosis.

The nuclear transcription factor NF-κB is involved in inflammatory responses and AP-1 is
important for cell growth and differentiation. p53 is a gene whose disruption is associated with
cancers. Jun, Fos are the transcription factor of AP-1. The mRNA of Fos and Jun, (c-Fos and c-Jun)
are found to be induced by relatively small amounts of hydrogen peroxide, superoxide, NO, and
ROS. Cells treated with hydrogen peroxide can cause the expression of c-Jun and c-Fos and
simultaneously increase the AP-1 transcription factor activity. The reason may be the fact that this
oxidative activation of AP-1 is based on the activation of JNK, a kind of MAPK. On the other hand,
NF-κB is involved in so many various responses, including inflammatory reactions, growth control,
and apoptosis [6]. The activity of NF-κB can be inhibited by antioxidants such as cysteine, and can
be activated by low concentration of hydrogen peroxide. That is because that ROS can mediate the
enhancement of IκB (inhibitor) degradation via oxidant modification. On the other hand, ROS can
influence the up-stream signal cascade.

Taking all above into consideration, ROS can interlace in the complex intracellular signal
transduction network. Instead of being ligand or inducing factors which can activate one specific
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molecule, ROS participate in many signaling pathways, either increasing or decreasing the effect
of some pathways. Redox state is similar to other biological indexes, pH and temperature, which
can be regulated by the system and can also regulate the overall cell performance.

2.3.5. ROS generated from exogenous free radicals

Tobacco smoke consists of two major fractions: solid (also referred to as tar) and gas phase.
These two fractions can be separated from each other using a standard glass fiber Cambridge filter.
Studies since 1980s have illustrated that gas phase and tar contain two very different populations of
free radicals[56]. Free radicals from tar are exceptionally stable that can be observed directly by
electron paramagnetic resonance (ESR) spectroscopy. Conversely, gas phase radicals are both less
stable and short-lived, and therefore cannot be observed directly by ESR [57].

Early studies hypothesized that all related tarry materials contain a single type of radical
consisting of an odd electron delocalized over a large aromatic quinone-like framework. Nowadays,
it has been proven that, out of the tarry polymeric materials in tobacco, the principle radicals which
give the major peak on the 2nd derivation of the ESR spectrum (g value from 2.0035 to 2.0038),
consists of quinone (Q), semiquinone (QH), and hydroquinone (QH2) [56]. Studies reported that
the source of these quinone, semiquinone, and hydroquinone radicals is the condensation of
catechol and 1,4-naphthoquinone, rather than polynuclear aromatic hydrocarbons (PAH) such as
pyrene or anthracene [58].
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According to the widely accepted hypothesis, superoxide and hydrogen peroxide result from
the reduction of oxygen by the hydroquinones and semiquinone radicals present in tar. However,
different groups used different equations to describe this mechanism.
Q+QH2→2H++2Q·Q·-+ O2→Q+ O2·-

Or
QH2+O2→QH·+O2·-+H+
QH·+ O2→Q+ O2·-+ H+

Or
Q+QH2→2 QH·+ O2·-+H+
QH·+ O2→Q+ O2·-+H+

In summary, no matter which equations are used, researchers agree on the fact that,
Q/QH·/QH2 system can generate semiquinone and/or quinone radicals spontaneously, which can
reduce oxygen to form superoxide O2·-. Later this high energy radical can reduce H+ ions to form
hydrogen peroxide [58].
2O2·-+2H+→O2+H2O2
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H2O2 can then be reduced to the hydroxyl radical (HO·) by metals such as iron (Fenton
reaction).

Furthermore, studies presume that the lack of fine structure in the ESR spectrum may attribute
to the rapid hydrogen atom transfer between the different quinone oxidation states. A polymer of
modest molecular weight present in tar would contain various quinone (Q), semiquinone (QH), and
hydroquinone (QH2) species. And these species can readily interconvert via hydrogen atom
exchange in such a complex Q/QH/QH2 system (Figure 3) [59].

Figure 3. Schematic representation of the Q/QH/QH2 equilibria in Q/QH2 polymers in
tar.
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Further investigation led to the hypothesis that the tar radical system is an equilibrium mixture
of semiquinones, hydroquinones,and quinones. It is suggested that this free radical complex causes
redox cycling that generates superoxide anion from molecular oxygen and leads to the continuous
formation of hydrogen peroxide and hydroxyl radical.

On the other hand, tar is highly sticky substance and it tends to gel along the nasal and tracheal
passage until the tar reaches alveoli in the lung. Tar deposits in the respiratory tract and initiates a
long-term generation of free radicals, which promote the inflammatory response. The adverse
effect of tar can be accumulated along over the years of smoking, owing to the long retention time
of the tar in the respiratory system [58].

2.4. Novel pharmacotherapy of COPD
As mentioned above, the traditional anti-inflammatory drugs, corticosteroids, have been
proven effective in asthma but found ineffective in COPD. The existing bronchodilator therapy is
directed to relief of symptoms, which has limited ability to cure the inflammatory reaction in the
lung. Thus, there is currently no effective treatment for COPD. Therefore, more effort is required to
develop new more efficient drugs for COPD.
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2.4.1. Mediator antagonists

The network of inflammatory mediators, including cytokines, growth factors, ROS, and lipid
mediators, induces chronic neutrophil inflammatory in COPD. If one were able to cut off some of
the links between the mediators and inflammatory cells by using antagonists or inhibitors, COPD
could be attenuated. These potential agents are summarized in Table 1 as other anti-inflammatory
drugs.

Lipid antagonists

LTB4, as mentioned above is a leukotriene, which is derived from membrane phospholipids by
the sequential actions of cytosolic phospholipase A2, 5-lipoxygenase (5-LO) and leukotriene A4
(LTA4) hydrolase. Macrophages and neutrophils are the main source of LTB4, and are the subjects
of its recruitment function. LTB4 receptor antagonists such as LY29311, SC-53228, CP-105, 696,
and so on, are found to inhibit the neutrophil chemotactic activity [60]. They are mainly the
antagonists of BLT1 receptor. Most of them showed significant anti-inflammatory effect in a
variety of diseases [61]. However, clinical studies on COPD have not been that positive. A study by
Gronke et al. attempted to evaluate the effect of LTB019 (one LTB4 receptor antagonists) on
inflammatory markers of COPD [62]. A 4 week double-blind, randomized, crossover trial of
LTB019 in 24 patients found that there were no significant differences between LTB019 group and
the placebo. The outcomes were the percentage of sputum neutrophils, total cell count, and the
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level of MPO, IL-8, and TNF-α. In addition, the FEV1 and FVC are also considered. Thus there is
still no evidence that LTB4 inhibition could be an effective treatment for COPD [63].

5-LO is a crucial enzyme in the production of leukotriene, thus its inhibitor has potential to
reduce the inflammatory. Some of 5-LO inhibitors act by interfering with the conformation of the
active sites while others act as antagonists to block the substrate binding site of the enzyme.
However, it has been difficult to develop a potent safe 5-LO inhibitor [64]. Thus, in the foreseeable
future, the application of lipid antagonist will still be limited.

Chemokine antagonist

The trafficking of all inflammatory cells is orchestrated by multiple chemokines. Thus,
blockage of chemokine receptors with selective antagonists might be an effective
anti-inflammatory strategy. Their potential is further confirmed by studies in animal model of
knocked out CXC receptor genes.

IL-8 is the most important chemokine in COPD inflammatory. As illustrated above it can
activate neutrophils via CXC receptors. Thus, one possible therapeutic approach could be the use
of an IL-8 antibody, and several studies illustrated that anti-interleukin-8 monoclonal antibody
derived from human showed inhibition of neutrophils inflammatory in animals and reduced the
chemotactic response of neutrophils. However, it is known that IL-8 activates neutrophils via
low-affinity G-protein-coupled receptor (CXCR1) and plays a chemotactic role via high affinity
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G-protein-coupled receptor (CXCR1). Moreover, other chemokine also can activate CXCR2, and
CXCR2 is also presented on monocytes. Thus, CXCR2 antagonists are more useful than IL-8
antibody [65]. Amino-terminal truncation of IL-8 and amino-acid modification are first produced
as CXCR antagonists. Several small-molecule inhibitors have been developed, including CXCR2
antagonists (e.g. SB332235), CCR2 antagonists (e.g. RS504393), CXCR3 antagonists (e.g.
NBI74330), and CCR5 antagonists (e.g. TAK220). These antagonists effect diverse therapeutic
effect on inflammatory [66]. The first small-molecule, non-peptide antagonist of CXCR2 is
SB225002, and it has selective affinity to CXCR2 [67]. Later many in vivo studies showed efficacy
of CXCR2 antagonists in IL-8-induced neutropenia in rabbits. Improved in vivo performance was
achieved by a CXCR2 selective antagonist of the same chemical series [68]. Later, more CXCR2
receptor antagonists were developed, such as

pyrazines/quinoxalines and growth-regulated

oncogene [69, 70] Although several papers highlight the dominating role of CXCR2 in COPD and
mention the potential of CXCR2 antagonists in the therapeutic of COPD, the performance of
CXCR2 antagonists in lung inflammatory was not established.

Many studies focused on another receptor antagonists, AMD3100, an antagonist of CXCR4.
Its effect in the reduction of allergic inflammatory in the lung is proven, and the mechanism of
action is decreasing of chemotaxis of lymphocytes. In addition, some antagonists for receptors to
CC chemokines may be of use since CC chemokines also play roles in recruitment of inflammatory
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cells in COPD [71]. Similarly, limited studies are focused on anti-inflammatory ability in COPD or
even other lung inflammatorys like bronchiolitis and asthma.

Even current studies hold considerable promise for the treatment of COPD by antagonists, but
additional systematic research is still necessary before the their application [72].

Cytokine inhibitor

TNF-α is an important cytokine in inflammatory, and thus TNF-α inhibitors are considered as
potential anti-inflammatory drugs. Infliximab is one FDA approved TNF-inhibitor. Infliximab was
initially produced for the treatment of Crohn’s disease. It is a novel chimeric monoclonal antibody,
anti TNF-α, which has both human and mouse fragments. This chimeric antibody has later shown a
therapeutic effect in patients with rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease and
psoriasis [73].

In patients with COPD, the level of TNF-α in the sputum and blood are increased, and the
genetic polymorphisms in the promoter regions of the TNF-α gene has been associated with
chronic bronchitis [74]. In addition, the increased on TNF-α level is found to be related to the
weight loss of the patient. Thus, blocking of TNF-α might have a beneficial response. Furthermore,
the study with mice lacking TNF-α showed less emphysema compared to the wild type after
exposure to smoke for 6 months [75-78].
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However, studies showed no therapeutic benefit in the evaluation of the efficacy of infliximab
in human subjects with moderate to severe COPD, not supporting the use of infliximab for COPD.
The impact of infliximab on malignancy risk in patients with COPD needs to be further elucidated
[79]. All in all no confirmed answer to the ineffectiveness of infliximab to COPD [80].

Antiproteases

Proteases, as mentioned above, play an important role in COPD, especially in emphysema.
The imbalance between proteases and antiproteases, leads to the destruction of the lung tissue in
the chronic phase of COPD. Thus, great effort has been directed to restore this balance through
the use of low molecule weight human elastase inhibitors. As illustrated above, neutrophil
elastase (NE) and Matric metalloproteinases (MMP, especially MMP-9) are two dominate
proteases in COPD.

For the inhibition of NE endogenous inhibitors were initially studied. One paper
summarized that there are at least three endogenous human neutrophil elastase inhibitors,
including α1-PI, secretory leukocyte protease inhibitor (SLPI) and elafin (also called elastase
specific inhibitor (ESI) or skin-derived antileukoprotease (SKALP) [81]. SLPI shows its
protective effect against protease mainly in the upper respiratory tract while α1-PI probably
works in the lower pulmonary field. Inhalation of SLPI with α1-PI were found beneficial in the
treatment of inflammatory lung disorder, including emphysema, chronic bronchitis, and cystic
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fibrosis [82]..

Later, synthetic neutrophil elastase inhibitors were developed, which are divided into two
categories: acyl-enzyme inhibitors and transition-state inhibitors. These molecules are considered
to be the new drugs for COPD. NE attacks the reactive carbonyl carbon of the acyl-enzyme
inhibitors, forming a tetrahedral intermediate. Later this intermediate collapses and forms a
relatively stable acyl-enzyme complex, thus preventing further hydrolytic process catalyzed by
NE. Many acyl-enzyme inhibitors are developed including: ONO-5046, MR-889, L-694,458,
CE-1037 and GW-311616 [82]. Most of them have been discussed as a potential treatment of
COPD. Some of them have been clinically tested for COPD. A 4 week double-blind randomized
and placebo-controlled clinical study was performed with MR-889. The safety of administration
was proven, but the therapeutic effect on COPD was not obvious [83]. Another group of synthetic
NE, transition-state inhibitors, is attacked by NE on the ketone carbonyl and forms a stable
tetrahedral intermediate. Also many transition-state inhibitors are in development, but limited
data of their effect of COPD is available.

Another important group of proteases in COPD is MMP. Many MMP inhibitors have been
developed including hydroxamate-based MMPIs, such as BB-1101, ADAM17, and CGS27023A,
and non-hydroxamated-based MMPIs such as BAY12-95666. One recent study analyzed the effect
of one MMP-9/12 inhibitor, AZD1236, on COPD [84]. AZD1236 is a potent, orally bioavailable
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inhibitor of MMP-9 and MMP-12, which showed high selectivity for these MMPs in vitro. From
this randomized, controlled, double-blind, multinational study, the trend of a reduction of
desmosine in both blood and urinary was shown, suggesting the possibility of a reduction in elastin,
but no significant therapeutic effect was demonstrated from the majority of biomarkers [85, 86].

Despite of all these results obtained from these studies, various problems that remained to be
solved in the clinical use of proteases inhibitor

NF-κB inhibitors

According to the previous discussion, NF-κB plays an important role in the expression of
many pro-inflammatory mediators, for example IL-8, TNF, and metalloproteinases, so the
inhibition of NF-κB seems useful to COPD therapy. Many ideas have been applied on NF-κB
inhibition, including gene transfer, inhibition of IκB kinase, and inhibition of NF-κB inducing
kinases. However, inhibition of NF-κB is always expected to have a side effect of the
compromising of the immune system [87] [88].

NF-κB induced gene expression can be triggered by a variety of physical and chemical
stimuli including cytokines, viral irritates. ROS, etc. and is controlled by a complex series of
proteins and enzymes. In resting cells, most NF-κB is bound to a protein inhibitor I κB which can
keep NF-κB in the cytoplasm. Triggered by the stimuli, the IκB is phosphorylated and
ubiquinated leading to a release of NF-κB. Free NF-κB can translocate to the nuclei and bind to
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specific DNA sequence, inducing gene transcription. The critical phosphorylation of the IκB is
performed by IκB kinase (IKK) complex. IKK is known to consist of two catalytic subunits
(IKK-1 and IKK-2) and a regulatory subunit IKKγ. IKK-2 is found to be 20-fold as active as
IKK-1 in the phosphorylation of IκB, and IKK-2 also can directly phosphorylate IκB. For this
reason, there has recently been studies for small molecular weight inhibitor of IKK-2 to inhibit
the inflammatory reaction from NF-κB [89] [90].

Several low molecular weight IKK-2 inhibitors have been developed. Thalidomide and its
analogs

have

shown

potential

anticancer,

anti-inflammatory,

anti-angiogenic,

and

immunosuppressive effects. Other small molecule inhibitors, including 15d-PGJ2 and PGA1
inhibit IκB degradation via forming a direct covalent bond to IKK-2 via cysteine 179 within its
activation loop. Later more selective inhibitors were developed, for example SPC-839, PS-1145,
and BMS-345541 [90].

In addition, other groups of inhibitors were developed. e.g. inhibitor of ubiquitination that
also block IκB degradation. Other inhibitors were found to prevent binding of NF-κB to DNA by
modifying NF-κB active site or occupying the binding site for NF-κB on DNA [91].

Among all these NF-κB inhibitors, IKK-2 inhibitors are the dominant and most developed
group. Some animal experiments were designed to study potential effect of these inhibitors in
COPD. In one study, a highly selective IKK-2 inhibitor, PHA-408 was orally administrated to
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rats exposed to LPS or cigarette smoke. Reduced inflammatory response rate was demonstrated
from the inhibitor, which is the first evidence that administration of IKK-2 inhibitor exerts
anti-inflammatory effect in vivo in rodent lung against cigarette smoking [92].

2.4.2. P38 MAP kinase inhibitors & Phosphoinositide 3-kinase inhibitors

When the inflammatory mediators activate the receptors on the cell membrane, the signal can
pass down to the gene transcription level by various pathways. The mitogen-activated protein
kinases (MAPK) plays a key role in these pathways. Thus, inhibitors of p38 MAPK have a broad
spectrum anti-inflammatory effect. Moreover, the phosphoinositide-3 kinase inhibitor could also
be a potent drug, since the knock-out of this gene is found to inhibit neutrophilic inflammatory. The
inhibitor targeting to proteases is also promising in COPD therapy. Studies just claimed the P38
MAP kinase inhibitor as potential COPD therapies, and limited studies focused on its application in
COPD or even on its anti-inflammatory efficacy [93] [94].

2.4.3. Non-enzymatic antioxidant

Exogenous ROS is known to be the initial main causal factor for tobacco induced COPD, and
endogenous ROS amplifies the inflammatory in COPD. Therefore the anti-oxidants can be
considered as potential therapeutic agents. Compared to all antagonists and inhibitors discussed
above, antioxidants, which may reduce the causal factor in COPD inflammatory, have recently
attracted much attention in COPD treatment.
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In a normal lung, GSHs are known as the buffer to defend the oxidative stress, and therefore
raising the GSH level by drug administration was considered by several groups. GSH can consume
ROS and convert into GSSG. However, direct administration, either via aerosolization or oral
administration, was found inefficient due to the short half-life and limited cell uptake of GSH [95].
An alternative approach of using a GSH precursor or another cysteine supplier was therefore
considered. Acetylcysteine also known as N-acetylcysteine or N-acetyl-L-cysteine (NAC) is one
example of a cysteine supplier. Some benefits were found after NAC oral administration, but the
effects were marginal, and the dosage for potential clinical benefit in COPD still remained to be
determined [96]. An alternative to NAC is N-acystelyn which can increase GSH more effectively
and is neutral in solution. In addition, other GSH donors have been explored as antioxidants. These
include erdosteine, fudosteine, and carbocysteine, which have the ability of reduction
exacerbations rates and improvement of life quality in long term [97]. However, recent studies
showed that, these antioxidants either were proven no beneficial in COPD patients, or still required
further evidence to illustrate their therapies[98].

2.4.4. Enzymatic antioxidant/ SOD

The redox imbalance in COPD mentioned above is not only caused by over-production of
ROS or too much exogenous ROS, but also by the limited level of antioxidant enzymes and
antioxidant small molecules in the affected respiratory tissue. Thus, a strategy of exogenous
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delivery of antioxidant enzymes to neutralize ROS in lung tissue could be a viable approach. The
most important ROS-detoxifying enzyme present in cells is superoxide dismutase (SOD). It
catalyzes the breakdown of superoxide radicals into less toxic oxygen and hydrogen peroxide, the
latter being further reduced by glutathione peroxide or catalase [99]. The metal cofactor of SOD
plays a role as an electron acceptor. Three major families of SOD are defined based on their metal
cofactor; the classes including copper/zinc SODs, iron/manganese SODs, or nickel SODs.
M(n+1)-SOD + O2− → Mn+-SOD + O2
Mn+-SOD + O2− + 2H+ → M(n+1)-SOD + H2O2.

Many studies on mice and humans have proven the anti-inflammatory effect of SOD on many
chronic inflammatory diseases, including myocardial ischemia, reperfusion injury, arthritis,
secondary spinal injury, Parkinson’s disease, and Alzheimer[100-102].

Some researchers focused on the anti-inflammatory effect of SOD in COPD. Studies have
proven that airway epithelium can be triggered by second-hand smoke exposure to release IL-8 in
vivo [103]. Mulligan RM et al, from the detection of IL-8, demonstrated that CSE (cigarette smoke
extract) is able to raise the inflammatory reaction on both upper and lower airway epithelium which
mimetics the situation in COPD. This pro-inflammatory reaction can be attenuated by SOD in vitro
[104]. According to this result, delivery of SOD to respiratory system could reduce the
inflammatory induced by tobacco usage in COPD.
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The safety and the anti-inflammatory effect of SOD have been proven by a double blind,
placebo-controlled clinical trial of PC-SOD, phisphatidylcholine SOD [105]. Tanka et al, found
that not only intravenous administration but also inhalation of PC-SOD ameliorated pulmonary
inflammatory, emphysema, and dysfunction, through suppression of cell death, decrease of
proteases, reduction of expression of proinflammatory cytokines and chemokine, and increase the
level of antiprotease in an animal model study. Thus, this modified SOD molecule was
therapeutically beneficial for COPD [106].

2.5. Inhalation drug delivery
An effective method to deliver drugs to the specific site of tissues or organs is always
challenging for pharmaceutics, especially for protein/peptides drugs, since their activity is closely
related to the conformation, and is very vulnerable to the gastrointestinal enzymes and the
phagocytic system in the circulation [107]. This leads to several new delivery approaches, and
pulmonary delivery is one of them. Basically, there are two kinds of pulmonary delivery, nasal and
oral inhalation drug delivery [108, 109].

The most obvious advantage of pulmonary delivery in COPD is its noninvasive nature, which
is especially important for some fragile drugs including proteins and peptides. In addition,
pulmonary delivery is a local delivery for respiratory diseases, which can have on site effect
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immediately after administration. This technique has been used to manage asthma and COPD for
more than 50 years. The earliest therapeutic agents, β2-agonists (LABAs) and inhaled
corticosteroids (ICSs) for asthma patients were initially delivered directly to the lungs. The inhaled
route offers a more rapid action compared to any systemic administration including injection. The
lung is an ideal site for inhalation delivery because of its high solute permeability, large absorption
area, and limited proteolytic activity. The solute permeability is extremely low in the lung
compared to other organs [110]. The surface area of the lung ranges from 75 to 140 m2 mainly from
500 million alveoli, while 2300 km respiratory tract has surface area of 0.25 m2. Due to local
delivery, the required therapeutic dosage of an inhaled drug can be decreased, thereby increasing
the safety of administration [111].

Because of the obvious advantages of the inhalation delivery route, it has also been
investigated by many research groups for systemic drug delivery [112-115]. This route offers many
advantages over the oral or injection administration for systemic drugs as the mucosa possesses a
well-developed vascular and lymphatic drainage system and the high permeability of the lung and
large absorption area also favor absorption of the systemic drug. Lastly, but most importantly,
inhalation drug delivery can circumvent first-pass metabolism in the liver and the pre-systemic
elimination in the GI tract [116].

Nasal delivery is a special case of inhalation drug delivery. The same as traditional oral
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inhalation, nasal delivery is originally applied for treatment of local diseases such as nasal allergy,
nasal congestion and nasal infection. Later, its systemic application has been exploited especially
for proteins and peptides, which are not easily administered by other routes other than by injection
[117] [118]. There are also two special applications where nasal delivery is especially important,
vaccines and nose to brain delivery. Nasal delivery of vaccines is promising especially for diseases
whose pathogenic microorganisms enter across the respiratory surface. The nasal mucosa is the
first site of contact with inhaled antigens and is also linked to nasal associated lymphoid tissue
(NALT), which can create both mucosal and systemic immune responses. On the other hand, the
possibility of nose to brain drug delivery offers one encouraging method to bypass the blood-brain
barrier (BBB) and reach the central nervous system directly from the nasal cavity. Many
researchers believe that a possible mechanism involves uptake by olfactory region rather than
direct diffusion to brain tissue or to cerebro-spinal fluid. Delivery efficiency is mainly dependent
on the molecule size and lipophilicity. Still many efforts are needed to enhance the fraction of the
drug that reaches the brain [117].

2.5.1. Size related particles deposition in lung

Though pulmonary delivery could be an ideal treatment for respiratory diseases, the drug
deposition site still needs to be addressed. For example, it has been proven that, although the β2
agonist receptor is mainly located at the alveolar wall, the smooth muscle located along the airway
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and terminal bronchioles is the major targeting site of these bronchodilators. In contrast, other
drugs are mainly targeting to either conducting airways or to the alveolar region. Since COPD
includes several different pathological mechanisms and the inflammatory occurs mainly at the
small airways and alveolar region, these would be ideal sites for anti-inflammatory drugs.

Despite the recent development of aerosol techniques, there are still many complex barriers,
which have to be circumvented if drugs need to reach the deep lung. The first one is the airway
geometry of the lung. The lung resembles an inverted tree, where the trachea or trunk subdivides
into two main bronchi and later consecutively branches into much more narrow and shorter
bronchioles. Specifically, the trachea undergoes 23 bifurcations before it reaches the alveolar sacs.
The first 16 generations are divided into the conducting region where the air is supposed to be
filtered and humidified. The rest is the respiratory region, which is mainly responsible for gas
exchange, and includes bronchioles, alveolar ducts, and the sacs. Therefore, the drug is likely to be
filtered before it goes deep enough into the lung via absorbing on the airways. Thus, many studies
focused on the fate of inhaled drug particles [119].

The site of deposition directly affects the efficacy of the inhaled drug. It is influenced
primarily by three factors: (a) particle/droplet size, coupled with density, surface properties, and the
shape; (b) anatomy of the upper and lower airways and the alveolar structure; (c) ventilator
parameters of the breathing pattern. The deposition of the particles along the airway is ruled by
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three principally different mechanisms: inertial impaction, gravitational sedimentation, and
Brownian diffusion. The size and geometry of the particle affect the aerodynamic diameter, which
can be conceptualized by considering a spherical particle settling under gravity through air, and are
quite different from the geometric diameter. It is defined by the equation:

=

Where ρ is the mass density of the particle, ρa is the unit density (1000 kg/m3) and dg is the
geometric diameter. Practically, a mass median aerodynamic diameter (MMAD) is applied to
indicate the inhaled particle size [119]. It is difficult to predict the actual site of deposition, since
anatomy differs among people, but from a general model and in vivo experiments, particles with a
MMAD of 5-10 µm are mainly deposited, or blocked at the large conducting airways and
oropharyngeal region (also called upper airway), by inertial impact. Particles with 1-5 µm in
diameter are deposited on small airways and can partially reach alveoli, and particles with ˂ 3 µm
in diameter have a chance to reach the respiratory bronchiole with around 50% of them depositing
in the alveoli. These particles’ deposition is mainly dominated by gravimetric sedimentation. Any
particles smaller than 1 µm, can remain suspended in the air, which can reach the lung easily and
deposit in the lung by random diffusion. However, large fraction of too small particles (˂ 0.1 µm)
can be lost due to exhalation. Moreover, particles ˂ 0.01 µm are blocked at the tracheal-bronchial
region due to too high diffusion coefficients (Figure 4) [120]. As mentioned above, since different
46

drugs have distinct targeting site, they are supposed to be formulated into different particle sizes.
Thus, inhalers generate micron size particles for the tracheal-bronchial tree (3-10 µm) or in the
alveolar region (1-3 µm) for systemic drug. Since anti-inflammatiory targeting site is in the deep
lung, small sized particles are required to be formulated [121].

Figure 4. Relationship between particle size and lung deposition: the trachea- bronchial
(T-bronchial) region consists of the windpipe and large airways; and the pulmonary
region consists of the small bronchi and the alveolar sacs.

2.5.2. Mucus clearance in the airway region

Once particles are deposited onto the epithelial lining of the lung, they first contact the
mucous layer within the airway or the surfactant-coated fluid layer within the alveolar region. The
mucus clearance system provides one of the most significant defense mechanisms against inhaled
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materials by removing and/or neutralizing alien toxic materials [122]. However, this also acts as
the strongest hindrance that limits the pharmaceutical efficiency of respiratory drug delivery.
Mucus (about 5µm in depth) is a viscoelastic gel layer that is exposed to the external environment
and is mainly composed of a three-dimensional network of cross-linked glycoprotein mucin
secreted by goblet cells and submucosal glands (Figure 5) [123-125]. Mucin monomers, each about
0.3-0.5 MDa are highly cross-linked or entangled, which gives the mucus its viscoelastic properties.
There is significant polydispersity in mucin’s molecular weight, and the data from different studies
show a wide range from 0.2 to 40 MDa. Mucins are coated with the diverse array of proteoglycans
[126] and thus they are negatively charged. Several systems are available to classify mucin fibers,
but generally they can be divided into two families: cell-associated mucins ranging between
100-500nm in length, which contains a transmembrane domain, and secreted mucins that are up to
several microns long [126-128]. In addition to mucins, mucus gels are loaded with cells, bacteria,
lipids, salts, proteins, macromolecules, and cell debris, with a shear dependent bulk viscosity that is
typically 103-104 times higher than that of water at low shear rates [129].

The mucus layer acts as the barrier to drug delivery, both local and systemic, via several
mechanisms, and these mechanisms supplement each other. First, the mucociliary clearance
rapidly removes the drug formulation from the lung to the gastrointestinal tract (Figure 5). Bacteria,
irritants and particles are stuck to the viscous mucus, and then are transported either downward or
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upward to the pharynx and later swallowed into the esophagus. The transportation is closely related
to the beating of the cilia present on the respiratory epithelial cells. With a beat of ~1000 strokes per
minute, the cilia pushes the mucus at a speed of ~5mm per min [130], making the half-life of a
polar drug such as protein very short (15-20 min). Secondly, the cross-linked mucin network
hinders the diffusion of a drug by steric obstruction, or by surface binding. This mechanism
constrains a substantial fraction of a polar drug in the upper layer of mucus, which has shorter
turnover time, compared to a lower layer of mucus. It also compromises the drug therapeutic
efficiency if the drug was designed to act inside the epithelial cells [129]. Finally, the drug trapped
in mucus is vulnerable to enzymatic degradation, especially if it is a peptide or an enzyme.

Thus, mucociliary clearance effectively eliminates particles that are unable to penetrate the
mucus network, which has pore diameters ranging from 20 to 800nm.
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Figure 5. Components of the mucociliary system: the cilia (hair type projections of the
epithelia cells), the periciliary fluid layer and the mucus. The mucus is secreted from
goblet cells and the submucosal glands. Mucociliary clearance is the primary
mechanism of clearance of mucus [131].

Thus, in order to efficiently deliver a protein drug such as SOD to the site of action and to
achieve optimum therapeutic performance, special drug delivery techniques must be utilized.
Unlike agonists and corticosteroids, which are hydrophobic, proteins are polar drugs and as such
are more likely to be hindered by the mucus layer.

Many strategies have been explored in an effort to overcome these barriers by the
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modiﬁcation of the peptide structure, the inhibition of the ciliary beat frequency, employment of
permeation or absorption enhancers, and the utilization of mucoadhesive polymers. Among these
strategies, improving mucoadhesion of particles in order to improve their retention at mucosal
surfaces is often utilized. This is due to the fact that mucus renewal is much slower than the transit
time of the luminal content. A variety of mucoadhesive drug delivery systems have been
engineered, driven by various interaction forces between mucus and drug particles, including
hydrogen bonding, van der Waals interactions, polymer chain interpenetration, hydrophobic forces,
and electrostatic interactions [132]. Nano-carriers have been considered as one of the tools to
improve respiratory drug delivery. Nano-size particles are favored because of their ability to be
trapped in mucin networks. As one example of a system that utilizes electrostatic interactions,
chitosan nanoparticles were exploited to improve mucoadhesion. Chitosan is cationic
polysaccharide composed of d-glucosamine and N-acetyl-d-glucosamine units. Mucus, as
described previously, is negatively charged, and can have ionic interaction with the positive amino
groups of chitosan. Chitosan can also enhance the paracellular absorption of polar drugs by
reversible opening of the tight junctions between the epithelial cells [133]. Several studies have
shown the application of chitosan as a nano-carrier that by provides a longer contact time for drug
transport across the mucus layer and endothelium membrane, before the formulation is cleared by
mucociliary clearance mechanism [134].
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However, other studies illustrated several fundamental limitations of this approach. The most
significant one is the toxicity of cationic nano-carriers. Mucoadehesive nano-carriers can
substantially alter the microstructure of mucus, and this disrupted mucus barriers cause greater
exposure to foreign materials, including pathogens and toxic materials.

Since the upper layer mucus (luminal mucus layer) is cleared more rapidly than the lower
layer mucus (adherent mucus layer)many recent studies are planned to achieve longer residence
time of particles by penetrating the luminal mucus layer, thereby reaching the adherent mucus layer,
and hence having a better chance to be internalized by epithelial cells [129].

For mucus penetration, particles must be nano-sized to diffuse through the mucin network,
and minimize hydrophobic entrapment by mucus. On the other hand, either anionic or cationic
charged particles may exhibit immunogenicity. Thus, in order to circumvent the immunogenicity
of delivery system, high hydrophilicity and neutral charge particles should be used. Poly (ethylene
glycol) (PEG) modified nanoparticles were reported as the agents able to penetrate the luminal
layer [135-137]. It has been argued that the improvement of drug delivery by PEG was most likely
due to the improved mucus penetration properties, rather than the mucoadhesion mechanism, since
the MW of PEG, around 2~10KDa, is too low to support adhesion via polymer interpenetration,
and the hydrophobic core of nanoparticle is well shielded by the PEG chains. According to an in
vitro study [65], the nanoparticles covered by dense and low MW PEG in fresh human undiluted
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mucus can achieve very high transport rate, which is only 6-4 times lower than the same particles in
water.

2.5.3. Clearance in alveolar region

Depositions on the alveolar region may be phagocytized and cleared by alveolar macrophages
or absorbed into the pulmonary circulation. Alveolar macrophages (AM) are the primary defense
system against inhaled microorganisms and toxic materials. The airside surface of each of the 500
million alveoli in the human lung is guarded and routinely monitored by 12-14 AMs. The deposited
particles are either transported through alveolar thin epithelial cells into the systemic circulation, or
phagocytized by AM and later cleared by ciliated airways or lymphatic system. According to the
lung physiology, this process can take from weeks to months, which could be quite enough for drug
delivery. In alveolar, for most protein drugs proteolytic degradation is not the main clearance
mechanism. In addition, nanoparticles demonstrated ability to escape from AM on some scale and
further prolong the retention time of drugs [81].

2.5.4. Advantage of nanoparticles in inhalation delivery

The main unique characteristic of nanomaterials is their size, which falls into the transitional
zone between individual molecules and the bulk material. The high surface to volume ratio leads to
more reactive groups on the surface. The use of nano-sized drug delivery vehicles (e.g.
nanoparticles or micelles) have led to interesting innovations in pharmacology. A number of
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nano-devices suitable for drug delivery made either of lipids or polymers are exploited for
therapeutic purpose to carry the drug in the body in a controlled manner from the site of
administration to the therapeutic target [138, 139]. In general, nano-carriers may (i) protect a drug
from degradation, (ii) enhance drug absorption by facilitating diffusion through epithelium, (iii)
modify pharmacokinetic and drug tissue distribution profile, and, (iv) improve intracellular
penetration and distribution, (v) a relatively uniform distribution of drug dose, (vi) enhanced
solubility of drugs, (vii) sustained release, (vii) decreased incidence of side effects, and (ix)
improved compliance.

Specifically, in a respiratory drug delivery system, nano-sized particles can offer advantages
in preventing deposition too early on the conductive tracts in respiratory system. In addition,
specially coated nanoparticles can penetrate the gel layer of mucus and escaping from
macrophages in respiratory system, prolonging the residual time. Many kinds of polymeric
nanoparticles have been formulated for pulmonary delivery mainly via nebulizers.

2.5.5. Inhalation drug delivery devices

Drugs have to be specially formulated to direct their entry to the respiratory system rather than
to the digestive system. This modification technique is called aerosolization. Modern aerosol
techniques provide stable dispersions of either solid or liquid drug in a gas medium. The drug
compound or the drug solution has to be broken up into small particles or droplets to form an
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aerosol that can be inhaled with air. Energy is required to counter the attractive force (hydrogen
bonds or van der Waals force) in solid drug or a solution and to form new surface of a smaller
particle or droplet. After these aerosolized particles are inhaled, they will deposit along the airway
of the lung by different mechanisms including gravitational sedimentation, inertial impaction and
diffusion. Currently, there are 3 common aerosol devices, which are used for pharmaceutical
application: Nebulizers, metered dose inhalers (MDI) and dry powder inhalers (DPI) [140, 141].

Nebulizers are among the traditional aerosol devices. One aerosol generator can formulate
drug dispersion in air and vent it to a mouth piece or mask. Aerosol is taken by a patient by
continuous normal tidal breathing. Based on different operating principles, nebulizers fall into two
categories: jet nebulizers or pneumatic nebulizers. Jet nebulizer uses high-speed air flow through a
nozzle that draws a liquid containing the drug and breaks the drug solution into droplets. In
pneumatic nebulizers, high frequency acoustic wave is used as energy source to break the drug into
droplets [108].

The most significant disadvantage of a nebulizer is inconvenience and lack of portability,
which limits it to uses mostly in a clinical setting. Thus, other portable unit-dose inhalers were
designed for household or everyday uses. One example is MDI, which contains pressurized and
liquefied gas, called propellant. Drug is suspended as a colloid or dissolved as a solution in this
propellant. When the propellant is released from the metered valve, it evaporates immediately,
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leaving dry drug particles, which can be inhaled. On the other hand, DPI is a passive inhaler, which
uses patient intake of air to entrain and disintegrate drug. The increased use of DPIs is owed to the
environmental concerns about chlorofluorocarbons that are commonly used as propellants in MDIs.
MDIs or DPIs is more difficult to use than nebulizers and requires appropriate technique. As a
result, a significant fraction of the asthmatic and COPD patients are unable to use MDI or DPI
effectively. Thus, training is necessary for the patients to have the correct technique. In contrast,
though traditional nebulizers are not as convenient, they provide continuous delivery over several
minutes rather than a single inhalation, and are much less dependent on the patient inhalation
technique.

Traditionally, the nano-sized drug delivery vectors were administered via nebulizers, using
aerosols with particle size in the range of 1-10 μm, each particle containing hundreds of
liposomes/nanoparticles with the size in the range of 100nm.

However, currently other disadvantages have gathered attention from the nebulizer. Besides
the inconvenience of the nebulizer device application, the stability of liposomes or other
nano-sized vehicles is compromised in colloidal suspension. The energy introduced by nebulizer
can induce the alternation of structure of nano-sized vehicles. Therefore, DPI was much preferred
as the approach to deliver liposomes or even other kind of nano-sized vehicles into lung.
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CHAPTER 3
SPECIFIC AIMS AND SIGNIFICANT
3.1. Overview
Glucocorticoids have been successfully utilized for the suppression of inflammatory in
several chronic inflammatory diseases including asthma, rheumatoid arthritis, and inflammatory
bowel disease. However, even a relatively high dosage of glucocorticoids results in a limited
efficacy in COPD compared to their effect in asthma or other inflammatory diseases. It was found
that the efficacy of glucocorticoids in COPD is compromised by the oxidative pressure in COPD
patients, and this effect knew as glucocorticoid resistance. We hypothesize that antioxidants can
restore glucocorticoid function by neutralizing the ROS. Thus, simultaneous administration of
antioxidants and glucocorticoids could be an effective approach to the treatment of COPD. The
long-term goal of this study is to achieve a significantly improved anti-inflammatory effect from
antioxidants and glucocorticoids.

For the purpose of this study, dexamethasone (DEX) will be used as the model glucocorticoid
drug because of its previous successful application in treatment of another inflammatory condition
in the lung (asthma). Superoxide dismutase is a broadly used antioxidant that has been studied and
shown efficacy in various inflammatory conditions [142]. In addition, low molecular weight SOD
mimetics are a promising alternative to SOD because of their higher stability and better
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intracellular uptake. Thus, these two molecules will be studied here as model antioxidants. Finally,
administration of free drugs is not expected to be efficient due to mucociliary clearance, and
therefore specially designed targeted nano-carriers will be utilized for simultaneous delivery of
both DEX and SOD/SOD mimetic to ensure prolonged residence time and sustained release of
drugs. Anti-mucin (anti-MUC1) antibody immobilized on the surface of the nano-carriers will be
used as the anchoring agent. The specific aims of this study are outlined below.

3.2. Significance
Chronic Obstructive Pulmonary Disease (COPD) is the fourth leading cause of death with
approximately 85% of these cases attributed to tobacco use [143]. Various toxins, especially free
radicals from tobacco smoke, generates reactive oxygen species (ROS) in the respiratory system,
causing a chronic abnormal inflammatory response that induces irreversible damage in the lung,
specifically airways fibrosis and alveolar wall destruction. No effective therapy is currently
available to prevent the exacerbation of COPD as current therapies only relieve the symptoms
rather than offering a cure. Various experimental efforts to reduce the degree of inflammatory by
using anti-inflammatory drugs have been proposed, but limited positive results from the clinical
trials.
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3.3. Innovation
 Although glucocorticoids have demonstrated encouraging therapeutic effects in the
treatment of asthma and other inflammatory diseases, it is hampered by the oxidative
stress resulting from COPD. Therefore, anti-oxidants administrated simultaneously with
corticosteroids appear to be a promising approach in treatment of COPD. Co-delivery of
these two distinct therapeutic molecules has been studied, the result showing a synergistic
effect in cancer treatment; however, this approach has not been tested in treatment of
COPD or other inflammatory diseases. This research addresses this need by proposing to
co-deliver an antioxidant (SOD or SOD mimetic) and DEX using targeted nano-carriers as
a delivery platform.

 Secondly, the proposed use of the anti-mucin1 antibody as a targeting ligand is a novel
approach. Targeted delivery is well established for other drug delivery systems for
intravenous administration, the targeting agents, for example an antibody, having the ability
to direct the drugs to the specific tissue needing treatment. However, this mechanism has not
been applied to inhalation administration. In the respiratory system, vigorous mucous cilia
movement removes the drug from the lung in a short time. In this study, the proposed
targeting antibody will selectively bind to mucin, which is the most abundant biomolecule on
the surface of epithelial cells.
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3.4. Aim 1: Preparation of nano-carriers for the targeted delivery of antioxidant and
anti- inflammatory drugs.
This aim will focus on the preparation and characterization of the polymeric NPs and
liposomes for loading the antioxidants and glucocorticoids. Several candidates of polymers and
lipids will be investigated to form distinct nano-carriers, and various methods will be utilized to
load drugs and targeting moieties. The subsequent analysis of the loading capacity and long-term
stability will help to choose the appropriate type of nano-carrier and determine the optimal drug
loading parameters. The information obtained in this aim is crucial for selecting the specific
nano-carrier system for later study.

3.5. Aim 2: The optimization of nano-carrier properties for maximum targeting
efficacy
The binding ability of an antibody-modified nano-carrier primarily depends on the number of
antibody molecules attached per nano-carrier. Even though the targeting and binding effect of
immune-modified

nano-carriers

has

been

addressed

by

many

researchers,

the

antibody/nano-carrier ratio has seen limited attention. More quantitative and real-time analyses of
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targeting are still needed for better understanding of the association and dissociation kinetics of
immune-modified nano-carriers. It is possible that the addition of the first few antibody molecules
may lead to a significant increase in the binding ability, while further addition may have moderate
or no effect. This specific aim proposes to determine the optimal antibody/nano-carrier ratio for
maximized binding.

3.6. Aim 3: In vitro evaluation of the protective efficacy of simultaneously delivered
antioxidant and glucocorticoid drugs
Previous research has found that glucocorticoid drugs, which are effective in other
inflammatory conditions, are blocked by oxidative stress in COPD, suggesting the potential to
restore its anti-inflammatory function by delivering antioxidants and glucocorticoids
simultaneously. Currently there is no cell culture or animal model of this glucocorticoid resistance.
Therefore, one important goal of this study is to develop a cell culture model, which would help
researchers to address glucocorticoid resistance induced by the oxidative stress. Once the model is
established, it will be used to test the hypothesis of the synergistic action of antioxidant and
glucocorticoid drugs.
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CHAPTER 4
PREPARATION OF NANO-CARRIERS FOR THE TARGETED DELIVERY OF
ANTIOXIDANT AND ANTI- INFLAMMATORY DRUGS
4.1. Introduction
It is widely accepted that glucocorticoids are able to suppress the inflammatory response,
one of its primary approaches being their ability to switch off multiple activated inflammatory
genes that encode cytokines, chemokines, adhesion molecules, and inflammatory enzymes. These
genes are usually not ready for transcription until they are released from the attached histones
octamer. This release is catalyzed by histone acetyltransferase (HAT) [144]. Pro-inflammatory
factors induce the production of NF-kappaB, which activates expression of HAT and thus directly
stimulates the expression of inflammatory genes. Once glucocorticoid binds to its receptor and
translocates to the nucleus, it activates expression of histone deacetylase-2 (HDAC2), which
counters action of HAT and reverses the process of expression of pro-inflammatory genes.
However, in COPD, exogenous oxidative stress impairs the translocation of the glucocorticoid
receptor and the activity of HDAC2 through the nitrosylation, oxidation and phosphorylation of
various factors, leading to the phenomenon known as glucocorticoid resistance [145].

Given that ROS plays a role as a pro-inflammatory factor, enzymatic antioxidants and
enzyme mimetics have been selectively applied in the treatment of various inflammatory diseases.
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For example SOD, the most widely used enzymatic anti-oxidant, has been found to have an
anti-inflammatory effect in myocardial ischemia, reperfusion injury, arthritis, and secondary
spinal injury [146] [147]. Many studies have shown the benefit of its administration, and one
study demonstrating that transgenic mice with another type of SOD (human Gu/Zn SOD) were
found to become resistant to an elastase- or cigarette smoking-induced COPD model, while the
SOD gene knocked out mice were found to be highly sensitive in the same model.

SOD mimetics may have several advantages over the native enzyme, including increased
stability, low molecular weight, better permeability through various barriers, and lack of
immunogenicity [148]. SOD mimetics also appear to have potential in treating inflammatory
caused by COPD [149]. Tanka et al. found that not only intravenous administration but also
inhalation of PC-SOD ameliorates pulmonary inflammatory, emphysema, and dysfunction
through the suppression of cell death, a decrease in proteases, the reduction of the expression of
pro-inflammatory cytokines and chemokine, and an increase in the level of antiprotease [106].
Since the anti-inflammatory effect of glucocorticoid is resisted by ROS, in addition to acting as
an anti-inflammatory drug directly, antioxidants are anticipated to restore the anti-inflammatory
function of glucocorticoids. The synergy effect is expected to result from the administration of
glucocorticoids and antioxidants simultaneously.

Nanotechnology has recently been exploited to enhance the pharmacokinetics properties and
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therapeutic index of various drugs. A large number of nano-carriers have been developed and
tested. Among these, polymeric nanoparticles (NPs) and liposomes represent two most studied
classes.

Application of nano-sized drug delivery systems in pulmonary drug delivery offer several
special advantages, including the possibility to achieve the uniform distribution in the alveoli. In
earlier studies, the suspension of nano-carriers was nebulized for inhalation. However, because of
the instability of drugs in solution and the aggregation caused by introduced energy during
nebulization, recent researchers preferred to lyophilize nano-carriers and administrate them by
dry powder inhaler (DPI).

Nanoparticulate carriers are capable of simultaneous delivery of two or more drugs, ensuring
all drugs are functional at the same location. Compared to deliver drugs separately, co-delivery of
multiple drugs has several potential advantages, including: 1) ensuring synergistic effects, 2)
simultaneously and the same place release, and 3) tenability of relative dosage of various drugs.
For example, many gene delivery systems have incorporated another drug to facilitate the gene
expression. However, in most cases, either two hydrophobic or two hydrophilic drugs were
loaded by the same approaches, for example emulsion and encapsulation. In this study, we
planned to design an appropriate nano-carriers to load both the antioxidants (SOD or SOD
mimetic) and glucocorticoids (dexamethasone) simultaneously.
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4.2. Materials and methods
4.2.1. Materials

HEPES buffer (#BDH4518) was purchased from VWR (West Chester, PA). AlexaFluor®594
(#A20004) fluorescent dye and octadecyl rhodamine B chloride R18 (#0246) were purchased from
Invitrogen

Life

Technologies

Corp.

(Carlsbad,

CA).

Cross-linker

Traut's

reagent

(2-iminothiolane·HCl) (#26101) was purchased from Thermo Scientific (Waltham, MA). SOD
from bovine liver (3000 u/mg, #574594) was obtained from Calbiochem (Gibbstown, NJ). The
SOD assay kit (#19160-1kF) was purchased from Sigma-Aldrich (St. Louis, MO). According to the
manufacturer’s information sheet, anti-NR1 antibody is specific to synthetic peptide corresponding
to the C-terminal region of rat NMDAR1 (amino acids 918-938). This sequence is identical in
mouse NR1, human NR1 (short and long forms), and rat NR1 isoforms NR1b, NR1c, and NR1f.
L-a-phosphatidylcholine,

hydrogenated

(Soy)

(#840058),

cholesterol

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(methoxy(Polyethylene
(mPEG2000-DSPE,

#880120),

1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-(maleimide(polyethylene

(#700100),
glycol)-2000)
and
glycol)-2000)

(MAL-PEG2000-DSPE, #880126) were purchased from Avanti Polar Lipid Inc. (Alabaster, AL).
poly (DL-lactide) (#531162, inherent viscosity 0.55-0,75 dl/g, MW 75,000-120,000),
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poly(L-lactide)-co-Poly(ethylene glycol) (#P2066, lactide: glycolide ratio 65:35, Mw
40,000-75,000), and rabbit serum Albumin were purchased from Sigma-Aldrich (St. Louis, MO).
Dextran 70 (#D1449, Mw 70,000) was purchased from TCI America (Portland, OR). Chloroform,
acetone and DMF were purchased from Calbiochem (Gibbstown, NJ). All other chemicals were
purchased from Sigma-Aldrich and were used without further purification. D(+) -sucrose and D(+)
-trehalose dehydrate were purchased from TCI.

4.2.2. Preparation of Lipid−Polymer Hybrid Nanoparticles

Conventional PLA-PEG NPs were prepared using the self-assembly method described by
Cheng et al. [150] . Briefly, the PLA-co-PEG and PLA polymer blend were prepared by dissolving
160mg of PLA and 40mg of PLA-PEG co-polymer in 16 ml acetone, and 10 μg octadecyl
rhodamine B (10 mg/mL in DMF) was added to this solution if label is needed. Later this organic
phase was gently added to 160 mL HPLC grade water in a glass beaker, agitated by ultra-sonication
(5510 Bransonic® Tabletop cleaner, Branson). NPs began to form due to the precipitation in water.
After 45 minutes of ultra-sonication, the PLA-PEG NPs were transferred into centrifuge tubes and
to remove excess reagents through repeated centrifugation (4500g, 0.5 h; Allegra® 64R centrifuge,
Beckman Coulter® USA). Specifically, the supernatant was removed after each centrifugation
round, and the NPs were re-suspended in the same volume of HPLC-grade water. Finally, the
purified NPs were concentrated into in 4 mL HEPES buffer (20mM, pH 8.5).
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For the preparation of the lipid−polymer hybrid NPs, 40mg of MAL-PEG2000-DSPE, an
artificial lipid-polymer, was used instead of the PLA-PEG co-polymer; these lipid−polymer hybrid
NPs later followed the same purification procedure as described above.

4.2.3. Preparation of the Liposomes

Liposome consisting PC: Chol: DSPE-PEG2000: DSPE-PEG2000-MAL at 55: 39: 4: 2
(molar ratio) were prepared by the thin film hydration method as previously described. Briefly,
lipid components were mixed and dissolved in chloroform and dried through rotary evaporation,
forming a thin lipid layer. Later, mixed lipid rehydrated by HEPEA buffer, and ultra-sonicated
using a probe sonicator (Omni Ruptor 4000, Kennesaw, USA) at 200 W output for 2 min. Total
lipid concentration consisted of 10 mg/mL.

4.2.4. SOD Conjugation to Nanoparticles and Liposomes

SOD was loaded on lipid−polymer hybrid NPs and liposomes, using the reaction between the
maleimide and the thiol group. However, since SOD from bovine does not have an available thiol
group, Traut’s reagent (2-Iminothiolane·HCl) was used to modify the SOD, adding thiol groups.
SOD was dissolved in mL HEPES buffer with 1 mg/mL (20mM, pH 6.5), while Traut’s reagent was
also dissolved in HEPES buffer (2 mg/mL) and then added to this SOD solution with a 20:1 molar
ratio. This mixture was kept in an incubator-shaker for 1 hour (280 rpm, room temperature). After
incubation, unlinked Traut’s reagent was removed through centrifugation using a microsep (10
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KDa MWCO). Concentrated modified SOD remaining on the top of the microsep centrifuging
device was collected and suspended in HEPES buffer, followed by multiple membrane washings
with HEPES.

For lipid−polymer hybrid NPs and liposomes, the modified SOD solution was added to the
suspension of the nano-carriers. Samples were then incubated overnight at room temperature. For
the NPs, modified SOD molecules that were not binding to the nano-carriers were removed using
repeated centrifugation (4500g, 30 min). For the liposomes, dialysis was used to remove the
non-bounded SOD molecules using Biotech Cellulose Dialysis Membranes (MWCO: 300,000,
Diameter: 10mm Spectrum). Dialysis membrane tube containing liposomes and with jaw
pinchcocks on both ends were immersed in a 1L of 20 mM HEPES buffer for 3 day dialysis.
Dialysis buffer was changed every 8 hours.

4.2.5. Bulk-loaded SOD-PLGA Nanoparticles

Bulk-loaded SOD-PLGA NPs were formulated using a double emulsion solvent evaporation
technique as described by Reddy et al. [138, 151]. Using a typical formulation procedure, PLGA
polymer was dissolved in chloroform (20 mg/mL), while an aqueous solution of proteins was
prepared by dissolving SOD in the HEPES buffer along with RSA (40 mg/mL of both SOD and
RSA). This mixture with 10:1 oil to water ratio was emulsiﬁed, forming a water-in-oil colloid
system through ultra-sonicating by a probe homogenizer (Omni Ruptor 4000, Kennesaw, GA) at 30
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W output. This water-in-oil emulsion was emulsiﬁed in a 5% w/v PVA solution also through
ultra-sonicating with 10:1 water to oil ratio. The emulsion was agitated overnight in an open
centrifugation tube in the chemical hood at room temperature to evaporate the chloroform. The
PVA polymer, un-incorporated SOD, and RSA were removed through repeated centrifugation
(4500g, 30 min). Finally, the suspension was reconstituted into HEPS buffer.

4.2.6. SOD mimetic encapsulation into liposomes and PLGA nanoparticles

MnTMPyP, a metalloporphyrin-based superoxide dismutase/catalase mimetic, is a
hydrophilic small molecule. Unlike SOD, SOD mimetics lack functional groups that can be used as
the reaction site for cross-linking. Thus, physical encapsulation was therefore applied to load the
SOD mimetic. The lipid cake after rotary evaporation was ultra-sonicated in the SOD mimetic
solution, and therefore, during the formation of Lipid bilayer, a portion of SOD mimetic was
encapsulated inside the liposomes. Non-encapsulated SOD mimetics were removed via dialysis.

For PLGA nanoparticles, the encapsulation procedure was the same as SOD, the double
emulsion method was applied, and centrifugation was used to remove non-encapsulated SOD
mimetics.

4.2.7. DEX incorporation in the hydrophobic structure of nano-carriers

DEX is a hydrophobic glucocorticoid. To achieve incorporation into PLA nanoparticles, it was
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dissolved in acetone along with PLA. Due to its hydrophobicity, DEX would co-precipitate along
with the polymer. In the case of liposomes, DEX was added to the lipid solution in chloroform
before rotary evaporation. During ultra-sonication, similarly to cholesterol, DEX would be
incorporated into the lipid bilayer.

4.2.8. Antibody Conjugation to Nanoparticles and Liposomes

As described previously, antibodies were modified using Traut’s reagent before conjugation to
lipid-polymer hybrid NPs or liposomes; for the bulk-loaded PLGA NPs, Diazirine crosslinkers
were used.

4.2.9. Analysis of SOD Activity

SOD activity was measured using an SOD assay kit (Sigma-Aldrich® Corporate life science),
which

uses

a

water-soluble

tetrazolium

(2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-terazolium

salt,

WST-1

monosodium)

to

produce a water soluble formazan dye (WST-1 formazan) upon interaction with superoxide.
Superoxide is generated by the xanthine oxidase/ xanthine system. The rate of the production of the
WST-1 formazan dye is linearly related to the concentration of the in situ generated superoxide,
which is reduced by SOD. The colorimetric method is utilized for detection since WST-1 is
colorless while WST-1 formazan has a characteristic absorption maximum of 450nm.
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A 20 μl aliquot of each sample (n=3) was added to a 96-well plate, followed by the addition of
the assay reagents. The plate was incubated at 37°C for 40 min, and the absorbance at 450nm was
read using a microplate reader (Bio-Tek Instruments, Inc.). The standard plot (from 0.1 to 100 U/ml
of SOD) was prepared by diluting known SOD concentrations in the dilution buffer provided by the
assay manufacturer. The inhibition rate was calculated using to the following equation:

Inhibition rate % = (((Ablank 1-Ablank 3)-(Asample-Ablank 2))/ (Ablank 1-Ablank 3)) x
100%

Since the most accurate determination of SOD activity occurs for SOD concentrations
between 1 and 20 U/ml, all samples with unknown SOD activity were diluted prior to conducting
the assay to ensure that their activity was within this range. To measure the total amount of
incorporated SOD excluding the influence from the polymeric shell for PLGA bulk-loaded NPs,
chloroform was used to dissolve the polymer after lyophilization. Then the immiscible SOD was
extracted from the chloroform using water and measured as above.

4.2.10. Characterization of the Prepared Nanoparticles and Liposomes

The hydrodynamic diameters of the NPs and liposomes were measured using dynamic light
scattering (DLS). A transparent cuvette was filled with 3 mL of HPLC grade water followed by
adding 1 μL of the sample. The suspension was carefully mixed using a pipette with special
attention being paid to avoid the formation of bubbles. Capped cuvette was placed in a 90 Plus
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particle size Analyzer (Brookhaven Instruments Corporation, Holtsville, NY) and DLS data were
read for 30 min (10 runs, 3 min per run). Zeta-potential was also measured using the 90 Plus
particle size analyzer with the electrode immersed in the suspension.

4.2.11. Lyophylization and Accelerated Aging Experiments

Lyophilization is a standard approach used to protect nano-carriers from degradation. Sucrose
and trehalose were applied as cryoprotectors. The common concentration of cryoprotectors is 10%
(w/v), and the 10X solutions were prepared in advance for storage. This concentrated cryoprotector
solution was added to the sample to achieve 10% concentration. Samples were frozen overnight at
-80 ºC before being lyophilized for 48 hrs.

To shorten the duration of the aging experiment, 37 ºC incubation was utilized to achieve an
aging rate of about 3 times faster than at room temperature. Although higher temperatures, for
example 50 ºC, could be used for other materials, these are not suitable for PLA and lipid, because,
the Tg for PLA is approximate 40 ºC, changing slightly based on polymer molecular weight, and
lipid tends to degrade above 40 ºC.

To detect the relationship between the SOD activity and its structure, circular dichroism (CD)
spectrum was used to analyze the structural change of SOD on liposomes during incubation at 37
ºC. CD spectra of SOD, estimated the percentage of α-helix, β-sheet, and other coils. Structural
information was collected at times (APPENDIX).
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4.2.12. In vitro drug release profile

Typically, the drug release profile of water-soluble molecules, such as SOD and SOD mimetic
in this study is performed in a physiological buffer solution, such as PBS. However, the water
insoluble molecules, such as DEX were not suitable for this method. One way to determine the
release profile is using a solvent that can dissolve the drug. However, it is not the way that the drugs
are released in the physiological situation; furthermore, most of such solvents also dissolve the
nano-carriers.

In the physiological situation, proteins, such as albumin bind to hydrophobic molecules and
facilitate their transportation. Thus, we proposed a novel method to study in vitro release using
dialysis against 3 wt. % bovine serum albumin (BSA) in PBS buffer, mimeticking the native
physiological conditions.

Liposomes with DEX were placed in 300 kDa dialysis tubes and dialyzed against 3% BSA in
PBS buffer. DEX concentration in the tubes was determined at different time point. The DEX
concentration can be assayed by absorbance at 283nm (the absorbance spectrum peak for estrogens
[152]). We determined DEX concentration at 0, 1, 2, 3, 5, 8 and 12 days. This experiment illustrates
the release profile of a hydrophobic water insoluble drug from the liposomes.
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4.3. Results and discussion
4.3.1. Single drug loading

Because of the advantages of nano-devices in drug delivery, they have already been explored
for delivery of SOD for various pathological conditions. Reddy’s group, for example, has studied
poly (lactide-co-glycolide) (PLGA) NPs loaded with SOD to protect human neurons against
hydrogen peroxide in vitro [138, 151]. They used a water/oil/water double emulsion method to
form hollow PLGA nano-shell which entrapped 75% of the initial protein into NPs, yielding 90 μL
of SOD per mg of NPs, equivalent to 400 U.

In addition to polymeric NPs, liposomes have also been used to deliver SOD, the results
indicating that they prolonged the circulation time. For example, Corvo et al. studied SOD
entrapped in liposomes with an extended period of the in vivo circulating using the
dehydration-rehydration method followed by extrusion [101].

All these studies with SOD encapsulated into nano-carriers showed promising result in drug
delivery. However, the therapeutic activity of these carriers may be limited by the rate of release of
the enzyme from nano-carriers at the site of action. Extensive research indicates that complete
degradation of PLA and PLGA NPs takes days to weeks; it takes hours to days to release most of
the incorporated drug in vitro, highly depending on the composition, size, and molecular weight
(Mw) of the polymer, and the properties of the incorporated drug [153-155]. On the contrary, the
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circulation time of these nano-carriers in the blood varies from minutes to hours after
administration, also depending on the size, composition, and Mw.

Because of these issues, Gaspar. et al. studied enzymosomes with surface-exposed superoxide
dismutase, which are PEGylated liposomes conjugated with acylated superoxide dismutase
(ac-SOD), expected to be more beneficial than encapsulated SOD [156, 157]. However, palmitoyl
chloride was applied to modify SOD to achieve covalent bonding to the liposome may significantly
alter the phydrophobicity of the SOD and then decrease its activity. In addition, Hu et al. have
developed novel lipid-polymer hybrid nanoparticles exposing maleimide groups on the surface of
NPs which can react with cysteine of proteins. These maleimaides, however, were designed to
immobilize targeting reagents originally rather than protein drugs, and lipid component with
maleimide can only be applied in NPs prepared through self-assembly approach [158].

In this study, the SOD was immobilized either on the surface of the PLA NPs and liposomes
or encapsulated inside double-emulsion PLGA NPs, while the SOD mimetic was loaded inside
the double-emulsion PLGA NPs or liposomes. Hydrophobic DEX was always incorporated into
the bulk of the nanoparticles or into the lipid bilayer of liposomes.

The SOD was first loaded on the surface of the liposomes by adding lipid-maleimide into the
liposome structure forming the available binding sites on the surface of liposomes and using a
cross-linker to form the covalent bond. With 2 mg/mL of 5000 u/mg of SOD added to the
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liposomes, the loading capacity was around 2000 U/mL (1930±575 U/mL) (Figure 6a).
Subsequently, the double-emulsion method was also investigated. Since the SOD solution was
encapsulated inside the PLGA double-emulsion NPs, its available SOD activity from the intact
PLGA NPs was low (205±50 U/mL). However, a much higher SOD activity was detectable after
the polymer shell was dissolved using an organic solvent. Total SOD activity measured after
removal of the polymeric shell was found to be 4140±1140 U/mL, however exhibiting a
significant variation (Figure 6a).

In addition, the same maleimide-terminated PEG-lipid was applied to modify the solid PLA
NPs forming a hybrid nanoparticle system. However, relatively low final SOD activity was
achieved (1040±176 U/mL) with the same initial concentration of SOD (Figure 6a). A further
experiment found that the final SOD activity was primarily based on the amount of the available
reactive moiety (the maleimide group) on the hybrid NPs or liposomes. Better coating by
maleimide-terminated PEG-lipid on the surface of the liposomes compared to the hybrid NPs led
to much higher SOD loading.

The hydrophilic SOD mimetic was encapsulated in both liposomes and double-emulsion
NPs. With the same initial activity, the loading capacity of the SOD mimetic for the PLGA
double-emulsion nano-carriers was much lower than for liposomes (3210±130 U/mL vs.
1310±450 U/mL), and the loading capacity of the double-emulsion NPs also exhibited more
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variation (Figure 6b). Such high variability is consistent with the complexity of the preparation of
double emulsion NPs, which includes two steps of ultra-sonication and chloroform evaporation
step, which inducing some undesirable leakage.

Similarly to bulk loaded SOD-PLGA NPs, the majority of SOD activity in the case of SOD
mimetic liposomes or SOD mimetic PLGA NPs was not available until the lipid bilayer was
broken via ultra-sonication or the polymeric shell was degraded by an organic solvent.
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Figure 6. Drug loading of several nano-carrier systems with a single drug. A. SOD was
covalently immobilized on liposomes and solid PLA NPs. Highest SOD activity was
found on intact SOD-liposomes. The total activity in the case of double-emulsion
PLGA NPs was much greater, but most SOD activity was not available until PLGA
polymer shell was degraded by organic solvent. B. SOD mimetic was encapsulated in
both liposomes and double-emulsion PLGA NPs, and liposomes possessed markedly
78

higher SOD activity. In addition, similarly to encapsulated SOD, most SOD mimetic
activity was not available until destruction of the nano-carrier. C. DEX was
incorporated into the lipid bilayer of the liposomes or co-precipitated in solid PLA NPs,
giving a similar drug loading.

DEX was loaded either into the core of PLA NPs or into the lipid bilayer of liposomes. Too
much DEX led to limited loading yield and presence of large DEX crystals in the suspension
detectable using optical microscopy. From preliminary studies we found that the initial DEX used
for the preparation of either PLA NPs or liposomes was not to exceed 5 mg/mL, resulting in a
loading yield of less around 30% in both cases (Figure 6c).

Table 2 summarizes the properties of the nano-carriers with single drug loading. Plain
nano-carrier samples were also included as controls. As shown in the table, liposomes were much
smaller than NPs. Previous research demonstrated that longer ultra-sonication leads to the smaller
size of the liposomes [159]. Meanwhile, the size of the PLA NPs was mainly dependent on the
molecular weight of the polymer. On the other hand, the size of double-emulsion PLGA NPs was
much larger than that of the liposomes or the hybrid NPs. Zeta-potentials were also measured, as
a characteristic of the stability of colloidal dispersions. As showed in Table 2, all had highly
negative zeta-potential below -40 mV, sufficient to ensure high stability of the colloidal system.
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There was no obvious change in either size or zeta-potential upon conjugation of SOD on the
surface of a nano-carrier.

Table 2. Summary of characteristics of nano-carriers both before and after the loading
antioxidants or glucocorticoids. The particle size was the number average measured by
DLS.

Liposomes (n=8)

PLA NPs (n=6)

SOD
Bare

SOD

SOD
DEX

Bare

SOD

mimetic

123.8

127.9

132.0

PLGA NPs (n=4)

SOD
DEX

Bare

SOD

mimetic

133.2

199.1

198.8

Size (nm)

DEX
mimetic

202.9

242.3

257.1

254.9

N/A

N/A

±25.0

±19.1

±27.7

±34.3

±44.3

±29.2

±8.2

±63.2

±43.0

±38.1

Zeta-potential -43.7

-49.8

-44.2

-42.9

-55.3

-54.2

-50.3

-63.2

-65.0

-60.3

N/A
(mV)

±5.4

±7.1

±4.0

±5.3

±4.3

±1.2

N/A
±6.4

±7.2

±4.6

±3.3

4.3.2. Lyophilization and long-term stability

Lyophilization is necessary for long-term self-storage. Stability of the nano-carriers after
lyophilization was evaluated by measuring changes in size, zeta potential, and SOD activity. As
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can be seen in Figure 7a, lyophilization resulted in a tremendous reduction of SOD activity in all
samples in the absence of cryoprotectors. However, use of cryoprotectors, sucrose and trehalose,
allowed us to prevent the loss of activity in all types of nano-carriers leading to retention of more
than 75% of the initial activity in all cases. Sucrose provided better protection than trehalose. It
was found that double-emulsion NP is much more vulnerable to the loss of activity after
lyophilization, even with cryoprotectors.
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Figure 7. Stability of SOD-loaded nano-carriers after lyophilization with and without
cryoprotectors (sucrose and trehalose). A. SOD activity decreased dramatically after
lyophilization without cryoprocectors, but cryoprotectors reduced the loss of activity in
all types of nano-carriers. B. Cryoprotectors prevented aggregation in all types of
nano-carriers. (*P<0.01, **P< 0.05, *** P <0.001)

In addition to the loss of activity, aggregation after lyophilization could be a concern for
drug-loaded nano-carriers. As can be seen from Figure 7b, size of the nano-carriers increases
considerably after lyophilization. The use of cryoprotectors allowed us to solve this problem.
Little size increase (<10% in all cases) was observed for the samples lyophilized with
cryoprotectors, while the size of the liposomes and double-emulsion PLGA NPs in the absence of
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cryoprotectors increased by 30% to 40%, a change attributed by partial aggregation. Much more
severe aggregation was detected in the case of unprotected lyophilized PLA nano-carriers
(830±10%).

The activity of the SOD-coated liposomes after long-term storage at 37 °C is shown in
Figure 8. This experiment compared the stability of the liposomes and the PLA NPs stored in
colloidal suspension to that of freeze dried samples with a cryoprotector. The samples stored as
colloidal suspensions lost more activity than their freeze-dried counterparts for both liposomes
and hybrid NPs. The lyophilized liposomes retained 80±3% of the original SOD activity with
trehalose, and 83±1% with sucrose after 120 days of incubation at 37°C, which corresponds to a 1
year shelf-life at room temperature. At the same time, liposomes stored in the solution retained
only 58±3% of SOD activity (P< 0.05). Similarly, the long-term stability of the hybrid NPs was
also higher for samples lyophilized with cyroprotectors. Here, samples with sucrose and trehalose
retained 85±2% and 83±5% respectively, while the colloidal suspension retained 73±4% of the
initial activity.

4.3.3. Glucocorticoid release profile

Unlike most water-soluble drugs, the transportation of hydrophobic molecules, for example
steroids, is facilitated by some proteins. Here, a new dialysis-based technique was established to
study the release of poorly soluble hydrophobic molecules from nano-carriers. Serum albumin
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was added into the dialysis buffer to facilitate the release of dexamethasone from the liposomes.

As seen in the Figure 9, the release of DEX in the liposomes in a buffer is restricted without
BSA because of its poor solubility on water. Free DEX suspension in the absence of liposomes
was removed completely from the dialysis tube within 2 days. In contrast, release from the
DEX-loaded liposomes was much longer and took more than 8 days.
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Figure 8. Long time shelf-life study for both SOD PLA (crosslinked) (A) and SOD
liposomes (B). With sucrose and trehalose cryoprotectors, 80% of activity was retained
after 120 days of accelerated aging at 37°C, which corresponds to 1 year shelf-life on
storage at room temperature. SOD activity immediately after freeze drying was
considered to be 100%. Nano-carriers without any cryoprotector (square); SOD
liposomes with sucrose (circle) and trehalose (triangle). *P<0.01, **P< 0.05, *** P
<0.001
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Figure 9. Drug release profile of DEX loaded liposomes. All free DEX sample was
released in 2 days, while liposomes resulted into a more continuous and prolonged
release. Drug was found not to release in BSA free buffer

In summary, sucrose performed better than trehalose as the cryoprotector. Hybrid NPs were
found to be less stable and more prone to aggregation than liposomes. Double emulsion PLGA
NPs showed lower SOD activity and were also found to be somewhat more vulnerable to
aggregation and loss of activity upon lyophilization. In addition, all three kinds of the therapeutic
molecules, SOD, SOD mimetic, and DEX, can be loaded into liposomes, and liposomes showed
better loading capacity of SOD and SOD mimetic compared to the other nano-carriers. Thus,
liposomes were selected as the delivery vehicle to load both antioxidant and glucocorticoids.

86

4.3.4. Simultaneous loading of antioxidant and glucocorticoid

The co-delivery system, loading two therapeutic molecules into one single nano-carrier,
reduces the dosage of nano-carriers and ensures their simultaneous release. Here two sets of
liposome samples were prepared, one with SOD loaded on the outer surface via covalent binding
and DEX loaded into the lipid bilayer, and the other encapsulating SOD mimetic inside the
liposome and DEX loaded in the lipid bilayer. As seen in Figure 10, there was no significant
decrease of the loading capacity of both the antioxidant and the glucocorticoids in these binary
systems. Unlike other co-delivery systems, where two types of therapeutic molecules were loaded
via the same mechanism, in this study, antioxidants and glucocorticoid were loaded using two
separate steps.

4.4. Conclusion
From the above results, liposomes were selected as the best nano-carrier that can carry both
antioxidants and glucocorticoids. Liposomes were more stable upon lyophilization and during the
long-term storage and allowed higher loading yield of both therapeutic molecules.
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Figure 10. The retained loading capacity in the co-delivery system. Both SOD+DEX (A)
and SOD mimetic+DEX (B) loaded liposome systems were prepared, and compared
with single drug design, these two systems retained most drug loading capacity.
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CHAPTER 5
THE OPTIMIZATION OF NANO-CARRIER PROPERTIES FOR MAXIMUM
TARGETING EFFICACY
5.1. Introduction
Currently, nano-sized delivery vehicles are the focus of much research for drug delivery in
treatment of various diseases [155, 160, 161]. Therapeutic molecules are packed into nano-sized
carriers, for example liposomes and polymeric nanoparticles, to selectively improve their
bio-availability, bio-compatibility and safety profiles; prolong circulation time; and reduce toxicity,
and with the continued development of techniques for nano-sized vehicle synthesis and research
enhancing their ability to address specific areas of need, it is expected that their utility in drug
delivery will continue to grow [162-164].

Among these techniques, modification of the surface of nano-sized vehicles to achieve
appropriate accumulation at the site of interest while at the same time reducing delivery to the rest
of the body has received much interest, because many drugs induce systemic side-effects in normal
tissue [165, 166]. Therefore, in addition to wrapping the drug in a well-designed package, its
preferential delivery to the site of interest can be expected to reduce systemic side-effects while
simultaneously increasing the therapeutic effect. This targeted strategy is a prominent area of drug
delivery research [164, 167].
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Active targeting is usually achieved by modifying the nano-sized vehicle with the molecules
which can bind to cells in the disease site. This binding and following cellular internalization
reduces the local concentration of the nano-sized vehicle, and then concentration gradients attract
more vehicles via free diffusion [168]. This binding not only facilitates the local accumulation but
also assists the internalization of the vehicle into the cells, which is essential for the drug functions
intracellularly [169]. Normally, this specific binding was obtained by modifying the surface of the
nano-sized vehicle with targeting ligands specifically recognizing disease-associated biomarkers.
Antibody (or antibody fragment)/antigen and ligand (or its structural analogues)/receptor couples
have been extensively studied for this targeting strategy, owing to their high specificity and high
binding affinity [170]. For example, folic acid receptors, overexpressed in several tumor types, act
as the pathology-associated biomarkers when drug-loaded nano-sized vehicles are modified by
folic acid or its structural analogues [171, 172], while vehicles designed to target endothelial cells
expressing the intercellular adhesion molecules (ICAMs) have been targeted using anti-ICAM
antibodies [173, 174].

The targeting efficacy of this surface modification, represented by the binding affinity from
the addition of a targeting entity through surface modification, has been demonstrated by numerous
studies [167, 175, 176]. More recently, several investigations have focused on targeting
performance, with the multivalent design having been shown to enhance targeting efficiency [171].
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Specifically, simultaneous binding of multiple agents on a single nano-sized vehicle to more than
one ligand/receptor leads to a synergistic or additive binding affinity, which is referred to as the
avidity effect. This effect has been found to significantly increase the apparent binding affinity, thus
raising the targeting efficacy [177, 178]. While this positive correlation between surface density
and the targeting efficacy has been widely accepted, some studies observed a surface density
saturation phenomenon. These researchers noted that once the surface density of a targeting agent
reached certain threshold value, its further increase did not increase the binding affinity; in fact, in
some cases it even decreased [179].

However, this relationship between the saturation phenomenon and the amount of targeting
agent was primarily investigated for ligand/receptor couples, and the targeting efficacy was
analyzed by the cell uptake rate of nano-sized vehicles and was difficult to quantify. In comparison
to ligand/receptor couples, antibody-modified nano-carriers have received much less attention,
raising the question of whether the saturation phenomenon is present in antibody-based targeting
systems. In addition, in vitro targeting experiments depend, in part, on cell viability, expression of
the receptors by cells in a specific set of in vitro conditions, and other cellular characteristics that
may introduce additional unknowns in the experiment. Moreover, the specific threshold value of
the surface density has not been clearly determined for the saturation phenomenon, something that
seems to be crucial for the design of nano-sized vectors and optimization of their targeting ability.
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Finally, the relationship between the threshold of the surface density and the properties of delivery
vehicles or other factors has not been fully investigated.

Here, we report a quantitative study of the saturation phenomenon of an antibody-modified
nano-sized vehicle system. In order to better understand the relationship between the surface
density of the targeting antibody and the targeting ability of the vector, we employed Surface
Plasmon Resonance (SPR), a powerful label-free method originally developed to study the
interaction between macromolecules [180]. Different from most static measurements, SPR is a
real-time measurement that allows direct determination of binding parameters such as affinity
constants and kinetic rates. SPR has been widely used to characterize the properties of
ligand-modified nano-sized vehicles targeting their corresponding receptors [171, 181-183]. While
the results of these studies have demonstrated the avidity effect via increasing the surface density of
the targeting molecule, it has not been employed to explore the saturation effect. In this study, we
use SPR to analyze the saturation phenomena for antibody-coated nanoscale carriers. For this
purpose, we used liposomes as a model nano-sized carrier.
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5.2. Materials and methods
5.2.1. Materials

Hydrogenated (Soy) (#840058), cholesterol (#700100), 1,2-distearoyl-sn-glycero-3-Phosphoethanolamine-N-(methoxy(polyethylene glycol)-2000) (mPEG2000- DSPE, #880120), and
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-(N-maleimide(polyethylene

glycol)-2000)

(MAL-PEG2000-DSPE, #880126) were purchased from Avanti Polar Lipid Inc. (Alabaster, AL,
USA). Dulbecco’s modification of Eagle’s medium (DMEM), antibiotic-antimycotic solution
(Anti-Anti), and fetal bovine serum (FBS) regular (Heat Inactivated) were purchased from Corning
Cellgro. Kaighn's modification of Ham's F-12 medium (K-F12) was acquired from ATCC. A
research-grade CM5 (carboxymethyl dextran) sensor chip was purchased from Biacore AB
(Uppsala,

Sweden).

NHS

(N-hydroxysuccinimide),

EDC

(N-ethyl-N-(3-dimethylamino-propyl)-carbodi-imide hydrochloride), ethanolamine/HCl and other
buffer solution reagents were purchased from Sigma-Aldrich. Anti-Glutamate Receptor NMDAR1
(NR1) antibody produced in rabbit. Anti-MUC1 antibody produced in rabbit, Anti-Mouse IgG
(whole molecule) antibody produced in goat, and monoclonal anti-hepatocyte growth factor
antibody produced in mouse were also purchased from Sigma.

5.2.2. Liposome preparation

PEGylated liposomes were prepared as described in previous studies [184]. The lipids used
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were phosphatidylcholine, cholesterol, mPEG2000-DSPE, and MAL-PEG2000-DSPE at the molar
ratio of 55:39:4:2. Total lipid concentration consisted of 10 mg/mL. Lipid components were
weighted as the molar ratio mentioned above, mixed and dissolved in chloroform (10 mg/mL), and
dried through rotatory evaporation, forming a thin lipid layer. These dried lipid films or cakes were
removed from the flasks, frozen, and stored. The mixed lipid film was subsequently rehydrated
with a HEPES buffer (20mM, pH=6.5) and dispersed using a probe ultra-sonicator (Omni Ruptor
4000, Kennesaw, GA, USA) at 200W output. Different sonication durations were applied to create
liposomes with different diameters. For assay requiring cell labeling, octadecyl rhodamine B dye
was added to the chloroform mixture right before rotatory evaporation. An ice-water bath was
applied to the lipid mixture preventing the heat from sonication, and then a 0.45 μm nylon syringe
filter was used to remove the large aggregations of liposomes formed during preparation which
reduced the polydispersity index (PDI).

5.2.3. Liposome characterization

Liposomes were diluted in deionized water to approximately 5 μg/mL as recommended in the
manual of particle sizer. Their mean particle diameter and the width of the particle distribution
(polydispersity index, PDI) were determined through the dynamic light scattering using a 90 Plus
Particle Size Analyzer (Brookhaven Instruments Corporation, Holtsville, NY, USA).
instrument was also used to quantify the particle charge as zeta-potential.
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5.2.4. Targeting ligand conjugation

The introduction of PEG modified with maleimide to the surface of the liposomes offered
potential binding sites for peptides or proteins. Maleimide reacts with thiol groups on the cysteines
of proteins, forming a stable carbon-sulfur bond, which has been widely applied to immobilize
proteins. For a higher loading yield, Traut’s reagent (2-iminothiolane•HCl) was used to modify the
protein as it reacts with primary amines (-NH2) to introduce extra sulfhydryl (-SH) groups while
maintaining charge properties similar to the original amino group (Figure 11).

Figure 11. Schematics for modifying liposomes with targeting antibody. (a)
Modification of the target antibody with sulhydryl groups. (b) Modified antibodies
binding to PEGylated liposomes with maleimide groups.

The conjugation method was described previously [184]. Targeting ligands or control
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antibodies were first mixed with Traut’s reagent at 20 molar excess and a final concentration of 0.01
mg/mL in a HEPES buffer (20 mM pH 8.0). After incubation for 1 hour in the dark at room
temperature, the unreacted Traut’s reagent was removed by microfiltration using 30 kDa MWCO
centrifugal devices. The modified proteins were then mixed with the liposome colloid in the
HEPES buffer, 20mM pH 6.5, and incubated overnight at room temperature. Unattached proteins
were removed through dialysis with the HEPES buffer (20mM) for 48 hours, replaced every 8
hours using Biotech Cellulose Ester (CE) Dialysis Membranes (MWCO: 300,000, diameter:
10mm).

5.2.5. BCA assay evaluation of targeting ligand surface density

The amount of target ligand immobilized on the liposomes was quantified through microBCA
assay. In order to eliminate interference from the lipid, 2% SDS was added to the samples. Traut’s
reagent-modified target ligands of known concentrations were included as standard samples.
Therefore, the surface density (Ab/μm2) and antibody/liposome ratio (Ab/liposome) were
calculated based on the amount of target antibody in addition to the average size of the liposomes
and the density of the lipids.
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5.2.6. Surface plasmon resonance (SPR)

Chip preparation

Quantitative and kinetic interaction of the antibody-modified nanoparticles with the antigen
was monitored using the Biacore X system, with data analysis being conducted using
BIAevaluation software. CM5 sensor chips were used in each experiment.

Ten mM HEPES, pH 7.4; 150mMNaCl; and 0.05% (vol/vol) tween 20 were used as the SPR
running buffer, and a 10mM sodium acetate (pH 4.0) buffer was used as the antigen immobilization
buffer. All buffers were filtered through 0.45 μm PTFE filters (Millpore) and sonicated for 30 min.
The antigen was immobilized through the following procedure (Figure 12): The chip covered with
modified dextran was activated with a solution of 70 μL EDC (75 mg/mL) mixed with NHS (12
mg/mL) at a flow rate of 10 uL/mL for 10 min. Then, the antigen solution in the sodium acetate
buffer was injected at a flow rate of 10 μL/min for 5 min. The concentration of antigens and the
replication of this injection were varied based on the requirement of antibody density on the chip.
The Biacore X instrument divided the sensor chip into two independent flow channels. Both were
activated by EDC solution, but one was closed during the antigen injection, serving as a reference
channel. Finally, both channels were blocked with ethanolamine (100 nM, 20μL/min), quenching
remained active binding sites.
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Figure 12. Schematics for modifying chips with antigen. Dextran fibers with carboxylic
acid groups on the chip were activated by EDC and NHS, and later form covalent bond
with amine groups on protein molecules.

SPR analysis

After the primer and normalization steps, samples of liposomes or free antibodies were
injected into both the reference and the detection channels at a flow rate of 5 μL/min along with the
running buffer. Liposome samples and free antibodies were diluted to create various concentrations,
and the analyses were conducted in triplicate to ensure accurate results. The sensorgram produced
by the Biacore X was recorded as a series of association (during the injection) and the dissociation
(after injection) phases for both the reference and the detection channels. Regeneration of the chip
surface was achieved using 3 M MgCl2 and 0.01% SDS (20 μL/min, 5 sec) in turn at a flow rate of
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40 μL/mL after each injection. The experiments were conducted using Biacore Control Software,
which automatically interprets the refractive index changes on the surface in resident unit (RU),
plotted over time. Then, BIAevaluation software was applied to determine the dissociation and
association rates and the binding affinity constant by fitting curves (obtained from the subtraction
of the reference channel signal from the detection one) into adsorption models.

Cell binding assay

Cells were grown as a monolayer culture in flasks at 37°C and under a 5% CO2 atmosphere in
a DMEM or K-F12 medium with 10% FBS and 1% Anti-Anti. Subsequently, they were passaged
into 96 well plates one day before the experiment. After the cells grew to a monolayer in the plates,
4% paraformaldehyde was utilized to fix the cells for 15 min. Then the cells were blocked by a
blocking solution (PBS with 1% goat serum albumin) for 30 min. Rhodamine-labeled liposomes,
modified with a targeting antibody in a series of dilutions, were incubated with the fixed cells at
room temperature for 4 hrs. A PBS buffer with 1% tween 20 was used as a washing buffer, and
washing was carried out 5 times after each step of the incubation. The amount of conjugated
liposomes on the cells was quantified using a fluorescence microplate reader. The fluorescence
intensity from Rhodamine at 575nm (excited at 552nm) was shown to be proportional to the
amount of liposome.
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5.3. Results and discussion
5.3.1. Liposome preparation

Liposomes were prepared from the PEGylated lipids containing maleimide end groups along
with cholesterol using a rehydration and ultra-sonication method. Figure 11 illustrates maleimide
chemistry used for modification of the PEG layer of the liposomes. As a result of that process, most
maleimide groups would be exposed outward since they are immobilized on the end of the PEG
polymer chains and form covalent bonds without any intervening spacer between the PEG and the
targeting antibody. These PEGylation liposomes with the lipid composition mimetic that of the
FDA-approved liposome drug, Doxil. The modification was less than 5% of the mass with the
addition of maleimide.

The resulting liposome sizes ranged from 100-300nm, inversely related to ultra-sonication
duration. According to previous studies, cavitation caused by oscillating micro-bubbles produces
shear fields. Large liposomes entering these fields form long tubelike appendages that can
pinch-off, creating smaller ones [159]. Thus, longer sonication duration results in smaller
liposomes. However, the zeta-potential of liposomes of various sizes remains constant. All samples
were approximately –45 mV, which was negative enough to maintain the stability of the colloid.
The final liposome concentration was found to be approximately 8.2 mg/mL, as determined by
gravimetric analysis, which corresponds to a concentration of 1012~1013 liposomes per milliliter.
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5.3.2. SPR Measurement

Because of high cost of the primary anti-MUC1 antibody, a model based on binding of a
secondary antibody was initially extensively analyzed before experiments with an actual targeting
antibody. In this secondary antibody model, anti-mouse IgG antibody produced in goat was utilized
as the targeting antibody, and a monoclonal anti-hepatocyte growth factor IgG antibody produced
in mice was used as the antigen.

Chip modification and pre-testing

According to the standard protocol designed for SPR studies of molecular interactions, the
antibody should be immobilized on the chip, while the antigen is running as the analyte along with
a running buffer. In addition, maintaining a low surface density of the antibody during chip
modification is recommended to avoid possible effect of avidity.

To better imitate cell interactions with targeted nano-carrier standard protocol for molecular
interaction experiments has been modified in this work. Specifically, the antigens rather than the
antibodies were immobilized on the CM5 sensor chip. The targeted antibody-modified liposomes
were injected into the flow channels to imitate flow transport of these nano-sized delivery vehicles.
The antigen immobilization was achieved through the EDC-based amide coupling method as
described in the CM5 chip protocol. For preliminary research, two different antigen-presenting
chips were prepared by varying the initial antigen amount. The CM 5 chip with a low surface
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density of antigen was prepared using the diluted antigen solution (10 μg/mL) according to the
standard protocol (Figure 13a). As demonstrated, both channels on the chip were activated by EDC
in combination with NHS, and then the antigen was immobilized on the detection channel, resulting
in the increase of approximately 500 resident unit (RU). Based on the instrument design, 1000 RU
is equal to 1 ng/mm2 protein; therefore 500 RU was equivalent to 0.5 ng/mm2 or approximately
2×109 antigens/mm2. From the literature, typical density of receptors on the cell surface is much
higher, in the range of 1010 antigens/mm2 or more [185] [186] [187]. To prepare a surface with a
higher surface density of the antigen, repeated injections of a higher concentration antigen
solution (200 μg/mL) were applied. A subsequent washing step removed any non-covalent linked
antigens (Figure 13b). In contrast to the earlier low surface density chip, the increase of 6000 RU
was achieved, equivalent to 6 ng/mm2 or 2.4×1010 antigens/mm2.

Both sensor chips prepared were assessed for binding specificity through the injection of free
targeted antibodies (Figure 13c). The curves shown in Figure 13c refer to a mean value obtained
from multiple independent measurements (n=3). With a consistent free antibody concentration,
various surface densities lead to different adsorption levels and kinetic parameters. Here, both
association and dissociation rates (Ka and Kd) were calculated through curve fitting analysis to a
simple 1:1 adsorption model (Langmuir model). The association constant (KA), representing the
binding affinity of the molecules to the surface, was calculated as KA=Ka/Kd. The detailed
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kinetic parameters and the affinity constants for the chips with different surface density of the
antigen are listed in Table 3. As expected, free antibody bound stronger to the chip surfaces with
high antigen density. This increase of affinity constant was due to the effect of avidity. High
density on the chip increased the possibility of forming multiple binding sites between the
antibody and the chip since each antibody has two binding sites (Figure 13d). As illustrated in
Table 3, the increase of the binding affinity for the high surface density of the antigen was caused
by both the increase in the association rate and the decrease in the dissociation rate independently.
The decrease in the dissociation rate ((kd low)/(kd high)≈10) was much greater than the increase
in the association rate ((ka high)/ (ka low)≈3), suggesting that the avidity effect, and hence the
increased binding affinity, depended more on the slowed dissociation step, possibly because of
the much lower probability of the simultaneous detachment of both binding sites [182]. By
analogy, liposomes modified by multiple targeting antibody molecules are expected to exhibit
much higher binding affinity, primarily because of the significantly slower dissociation process.

Rmax, representing the theoretical maximum signal for each single run, was extrapolated
using BIAevaluation software. As shown in Table 3, the ~12-fold increase in the surface density
of the antigen resulted in only approximately a 3-fold increase of the Rmax for free antibody
binding. Thus, there are multiple unoccupied binding sites on the surface; formation of multiple
bonds between the antibody and antigen also could be a contribution (Figure 13d).
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Considering the surface density of more than 1010 molecules per mm2 for a typical target
ligand, such as folate receptors on cancer cells, NMDA receptors on neurons, or Epithelial
membrane antigen (MUC1) on the surface of epithelial cells [188] [189], the chip with the high
antigen concentration was deemed to be more appropriate for further investigations.
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Figure 13. CM 5 sensor chip preparations with various antigen densities and pretest
with free antibody samples. (a) Sensor chip with low density antigen was prepared by
one-time diluted solution injection. (b) Sensor chip with high density was prepared by
repeated concentrated solution. (c) Both sensor chips were tested through the free
targeting antibody solution of the same concentration. (d) Schematic of the free
antibody immobilization on sensor chips both high and low density surfaces.

105

Table 3. Kinetic parameters and constants of free antibody binding to both low and high
density antigens on the sensor chip surface.

Chip surface

Rmax (RU)

ka (1/Ms)

kd (1/s)

KA (1/M)

Low surface density

1.9 (±0.4)×103

2.4 (±0.7)×104

3.7 (±0.6)×10-4

6.5 (±2.0)×107

High surface density

6.0 (±1.0)×103

8.0 (±1.8)×104

3.4 (±0.4)×10-5

2.4 (±0.6)×109

Surface density of antibodies on liposomes

Liposome samples (130nm), with a range from 4 to 14 molecules per liposome particle, were
prepared by manipulating the initial antibody concentration during liposome formation (Table 4).
The final antibody amount per liposome particle was assessed through microBCA assay. As the
table illustrates, the maximum antibody loading of this liposome composition was approximately
14 antibody molecules per vehicle. The liposome samples with no antibody modification or with a
non-targeted antibody (anti-bovine antibody) served as the control that was tested in advance, the
results indicating that the nonspecific binding to the chip surface on plain liposomes and on the
liposomes with the control antibody was negligible (APPENDIX).

Antibody-amount dependent binding sensorgrams were acquired by running these samples
through the chip with a high antigen surface density (Figure 14a). As shown in the figure, the
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dissociation step was much slower than that for the free antibody, and thus a prolonged dissociation
was used to enhance the accuracy of the fitting. The dissociation phase lasted more than 20 min for
every injection (not fully demonstrated in the figure). Previous research has found the Langmuir
model to be appropriate for evaluating the targeting efficacy of antibody modified delivery vehicles.
The binding affinity calculated from the curve fitting is shown in Figure 14b, and more detailed
kinetic results are shown in Table 4. As illustrated by the figure and the table, from low targeting
antibody surface density on liposomes to high, the binding affinity increased significantly at low
surface coverage, from (0.6 ±0.2)×1010 M-1 at 3.8 antibodies per liposome to (2.3 ±0.3)×1010 M-1 at
5.8 antibodies per liposome, but later it reached a plateau at ~9 targeting antibodies per liposome
particle, or 1.5×108 antibodies/mm2. After that point, further addition of the targeting antibody on
the liposomes did not significantly increase the binding affinity ((6.0±1.3)×1010 M-1 at 13.5
antibodies per liposome vs. (1.6)×1010 M-1 at 9.2 antibodies per liposome). The saturated binding
affinity was found to be approximately ～6.0×1010M-1. This result has shown that, similarly to the
conventional ligand/receptor targeting, this targeted nano-carrier/antigen system also met the
saturation point at certain antibody coverage, and the apparent binding affinity remained stable
with further increase of the antibody surface density.

Similarly to the free antibody, the increase in binding affinity from low to high targeting
antibody density was attributed to the reduction of the dissociation rate and the increase in the
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association rate. Both kinetic rates also reached a plateau at some point (~24×104 (Ms)-1 for ka and
4.2×10-6(s-1) for kd) (Table 4).

The association rate of liposomes with a low targeting antibody surface density
((3.9±0.6)×104(Ms)-1 at 3.8 antibodies per liposome) was somewhat lower than that for the free
antibody ((8.0±1.8)×104(Ms)-1) The reason for this result might be much larger size of the
liposomes compared with the free antibody. It is known that the association rate is partially
determined by its diffusion rate, which is negatively related to its size. However, with the further
increase in the amount of antibody on the liposome, the avidity effect suppressed the negative
impact from the increased size. On the other hand, compared to the free antibody, the dissociation
rate, which contributes the most to the rise in the binding affinity, of the antibody-modified
liposomes was reduced by an order of magnitude. This trend further inferred that the increase of
association constant, derived from multivalent binding, was mainly contributed by the
significantly reduced dissociation rate, meaning that the avidity effect was primarily from the
lower probability of simultaneous dissociation of two or more bonds.

Table 4. Characteristics and targeting efficacy of liposomes (130 nm) with various
targeting antibody surface densities.
Initial amount

Loading yield

Antibody per

Antibody
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Rmax (RU)

ka (1/Ms)

kd (1/s)

(ug/mL)

(%)

liposome
Per mm2

Lip (130, 3.8)

25

81.4(±23.6)

3.8(±1.1 )

0.7(±0.2 )×108

1.5(±0.2)×103

3.9(±0.6)×104

6.5(±2.0)×10-6

Lip(130, 5.8)

50

62.4(±10.8)

5.8(±1.0)

1.1(±0.2 )×108

1.9(±0.3)×103

10.9(±1.7)×104

4.7(±0.6)×10-6

Lip(130, 9.2)

100

49.5(±7.0)

9.2(±1.3)

1.8(±0.3 )×108

2.4(±0.3)×103

24.2(±4.1)×104

4.4(±1.0)×10-6

Lip(130, 13.5)

150

48.2(±5.4)

13.5(±1.5)

2.6(±0.3)×108

2.6(±0.4)×103

25.2(±4.5)×104

4.2(±0.7)×10-6

Lip(130, 14.2)

200

37.6(±5.3)

14.2(±2.0)

2.7(±0.4)×108

2.1(±0.4)×103

23.7(±5.2)×104

4.3(±0.5)×10-6

A parameter, β, was used to represent the increase of the apparent binding affinity form the
avidity effect. In this case, β for the sample with saturated targeting antibody was approximately
23. Different from most previous studies, owing to the technique of SPR, the association constant
was quantitatively determined, which not only enabled the comparison between different samples,
but also with free antibody’s association constant. In the future, this approach can also be used to
compare different delivery systems and will be helpful to further investigations of the avidity
effect.
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Figure 14. (a) Sensorgrams of liposomes (130nm) with various target antibody surface
densities. To precisely determine the dissociation rate, a prolonged dissociation phase
was conducted up to 20 min, but was not fully demonstrated. (b) A plot of binding
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affinity as a function of target antibody surface density. Surface density was interpreted
in two ways: antibody per liposome ratio, and antibody per millimeter square.

As shown in Table 4, liposomes with a high targeting antibody surface density resulted in a
much higher Rmax than liposomes with low surface density of the antibody. Since the binding
sites on the sensor chip were abundant, the steric occupation of the surface was the primary
limitation for the theoretical maximum signal. Liposomes were negatively charged to repulse
each other, maintaining stability in the colloid. This repulsion decreased the bulk density of
liposomes on the surface, leading to a low Rmax for a low targeting antibody surface density.
However, liposomes with a high targeting antibody density exhibited a much higher Rmax, up to
50% of the chip surface. This increased Rmax could be associated with high avidity, which forces
liposomes to pack much closer onto the chip surface.

Size of liposome

The diameter of liposomes and other nano-sized vehicles is a crucial parameter in
pharmacokinetics as their size provides the potential for crossing the various biological barriers in
the body. However, limited research has focused on the effect of the size of a nano-carrier on it
targeting ability. Here, we first prepared muchlarger liposomes (280nm) by reducing thee
sonication duration. Similarly to the smaller liposomes used in the experiment described above
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(130nm), a series of samples with various targeting antibody surface densities was prepared using
a similar procedure. With a much larger surface area but a consistent maleimide content in the
liposome composition, larger liposomes with more targeting antibodies per liposome (up to 73
antibodies per liposome) were available (Table 5). Similarly to the smaller liposomes, the changes
in the SPR sensorgram were observed with the increase of the surface density of the targeting
antibody, and saturation was reached at some threshold surface density as indicated by the
overlapping kinetic curves in

Figure 15a. Both the positive correlation and the saturation are illustrated in the binding
affinity plot (

Figure 15b) and more detailed parameters are shown in Table 5: initially, as the surface
density of targeting antibodies increases, the binding affinity increased quite dramatically ((0.3
±0.1)×1011 M-1 at 10.7 antibodies per liposome vs. (1.2 ±0.3)×1011 M-1 at 21.6 antibodies per
liposome), and as the amount of the targeting antibody increased, the increase in the binding
affinity reached saturation at ~40 antibodies per liposome with the saturating binding affinity of
~2.2×1011 M-1.

The threshold of the targeting antibody amount per liposome for larger liposomes was much
larger than that for the smaller liposomes (~40 antibodies per liposome vs. ~9 antibodies per
liposome, respectively). However, saturation occurs at approximately the same antibody surface
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density of ~1.5×108antibodies/mm2, independently of the size of the liposome. These results
indicate that the surface density (antibodies/mm2) rather than number of antibody molecules per
liposome determines the saturation of the targeting affinity of these particular nano-sized delivery
vectors.

Table 5. Characteristics and targeting efficacy of liposomes (280 nm) with various
targeting antibody surface densities.
Initial amount

Loading yield

(ug/mL)

(%)

12.5

94.2(±15.6)

Antibody

Antibody
per liposome

0.4(±0.1 )×
Lip (280, 10.7)

10

0.8(±0.1 )×
25

95.6(±9.2)

1.2(±0.1 )×
50

64.8(±2.8)

10

1.8(±0.2)×1
100

48.0(±5.7)

0

2.9(±0.1)×1
150

52.3(±1.9)

0

3.0(±0.2)×1
200

40.5(±2.6)

17.1(±0.29)

0

1.1(±0.3)×1

4

0

16.9(±3.2)×

×10-7

14.6(±0.23)

03

1.7(±0.4)×1

104

19.9(±3.2)×

×10-7

3

0

3.0(±0.6)×1

4

14.4(±0.22)

10

29.7(±4.2)×

×10-7

3

0

3.1(±0.6)×1

4

12.6(±0.18)

10

26.7(±3.3)×

×10-7

12.0(±0.16)

71.0(±2.6)
8

Lip(280, 73.4)

4.9(±1.0)×1

3

43.5(±5.2)
8

Lip(280, 71.0)

0.7(±0.2)×1

29.3(±1.2)
8

Lip(280, 43.5)

kd (1/s)

21.6(±2.0)
108

Lip(280, 29.3)

ka (1/Ms)

10.7(±1.8 )
8

Lip(280, 21.6)

Rmax (RU)
Per mm2

3

0

3.1(±0.5)×1

4

10

30.5(±2.7)×

×10-7

12.3(±0.15)

73.4(±4.8)
08

03

104

×10-7

Research on liposomes of different sizes but similar targeting antibody density, for example
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Lip (130, 5.8) and Lip (280, 29.3) (Table 2, and 3), demonstrated that the association rate did not
increase as the size did, but on the other hand, the dissociation rate was reduced significantly,
leading to the increase of the affinity constant as the size of the liposomes increased from 130 nm
to 280 nm. Based on these observations, one can conclude that similarly to the increase of the
antibody, increase of the size of the liposomes increases the association constant by reducing the
dissociation rate.
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Figure 15. (a) Sensorgrams of liposomes (280nm) with various target antibody surface
densities. To precisely determine the dissociation rate, a prolonged dissociation phase
was conducted but was not fully demonstrated. (b) A plot of binding affinity as a
function of target antibody surface density. Surface density was interpreted in two ways:
antibody per liposome ratio and antibody per millimeter square.
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Figure 16. A plot of binding affinity as a function of the liposome size. All three
samples were modified with enough target antibody to reach the saturation.

To further study the effect of size, samples of intermediate sizes (183nm) were prepared and
modified with sufficient antibody density to reach the saturation point of 1.5×108antibody/mm2.
Then, the determination of the targeting ability was compared for these intermediate sized
liposomes to Lip (130, 13.5) and Lip (280, 73.4) as shown in Figure 16. With a similar surface
density of the antibody, larger liposomes possessed a higher association rate and a much lower
dissociation rate. The most likely explanation for this result is the smaller curvature of larger
liposomes, suggesting more surface area available for the contact with the sensor chip. With
similar targeting antibody surface density, more targeting antibody molecules on larger liposomes
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could bind to the antigen on the surface, causing a more pronounced avidity effect. On the other
hand, the Rmax also increased along with the binding affinity, inducing closer packing of larger
liposomes on the chip surface.

Thus, with the same ratio between the targeting antibody and the constructive lipid, larger
liposomes offer much higher association constant and binding affinity than smaller ones.
However, liposomes with smaller size may have other advantages in drug delivery, for example
the ability of freely going through certain biological barriers. Thus, the size of the liposomes
should be carefully considered according to their particular application.

Primary antibody

Results from these experiments indicated that the binding affinity depends on the targeting
antibody surface density and liposome size for the secondary antibody model. This raises the
question of whether a primary antibody, an actual targeting reagent, will follow similar trends and
reach a similar saturation point. Thus, a primary antibody model was developed with anti-mucin1
fiber antibodies in conjunction with a mucin fiber antigen. Mucin fibers are heavily glycosylated
proteins (glycoconjugates) produced by epithelial tissues. Mucin-1 (MUC1) is a cell surface
associated mucin linked to the apical surface of epithelial cells, thus, providing a good target for
epithelial cells. In addition, many kinds of cancer cells overexpress MUC1, offering a potential
target for cancer therapy. Anti-MUC1 antibody was previously used as the targeting agent [190]
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[191].

Table 6. Characteristics and targeting efficacy of liposomes (116 nm) with various primary
targeting antibody (anti-MUC1) surface densities.
Antibody

Initial amount

Loading yield

Antibody per

(ug/mL)

(%)

liposome

Per mm2

Lip (116, 3.3)

25

70.0(±10.5)

3.3(±0.5)

Lip (116, 5.3)

50

57.0(±7.3)

Lip (116, 8.4)

100

Lip (116, 12.2)

150

Rmax (RU)

ka (1/Ms)

kd (1/s)

0.8(±0.1)×108

8.1(±0.4)×102

2.3(±0.3)×104

10.5(±1.0)×10-6

5.3(±0.7)

1.3(±0.2)×108

1.3(±0.6)×103

7.5(±0.7)×104

7.6(±0.9)×10-6

45.0(±6.6)

8.4(±1.2)

2.0(±0.3)×108

2.0(±0.11)×103

17.2(±2.3)×104

7.3(±1.0)×10-6

43.3(±4.0)

12.2(±1.1)

2.9(±0.3)×108

2.1(±0.10)×103

17.5(±1.2)×104

7.0(±1.1)×10-6

Similarly to previous experiments, we immobilized MUC1 fragments on the chip using the
same mechanism of EDC, resulting in 3×1010 antigen molecules/mm2, equivalent to 3 ng/mm2.
Sensorgram from free antibody analysis indicated a binding constant of anti-MUC1 (9.0±1.1)
×108 (M-1), which was lower than that for the secondary antibody because of the lower binding
affinity of anti-MUC1.
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Figure 17. (a) Sensorgrams of liposomes (116nm) with various primary target antibody
surface densities. (b) A plot of binding affinity as a function of target antibody surface
density.
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Another set of the liposomes (116nm in diameter) was generated with varying surface
densities of anti-MUC1 antibody (Table 6), Sensorgram for these samples are shown in Figure
17a. The binding affinities seen in Figure 17b were found by fitting these results into the same
Langmiur model as previously. Similar saturation trend was observed at approximately 1.5×108
antibody/mm2. Detailed kinetic parameters are shown in Table 6.

In addition, as seen in the free anti-MUC1 sensorgram, the slower dissociation rate again
contributed to the increase in binding affinity, indicating the avidity effect relied on the reduced
chance of the antibody detaching from the surface, which is similar to the secondary antibody
model previously described (Table 6). The trend of Rmax, the theoretical maximum signal for the
sensorgram was also similar to that observed in the case of the secondary antibody. By comparing
the binding affinity, β, of the targeted liposomes to that of the free anti-MUC1 antibody, the
avidity effect parameter for samples upon reaching the saturation was found to be ~22, consistent
with the previously studied secondary antibody model with similarly sized liposomes (130 nm).

These results suggest that the saturation trend, avidity effect, and the saturation point of the
targeting antibody surface density were not influenced by the type of targeting antibody or the
size of the delivery vehicle, at least in this liposome model. These trends also appeared to be
independent on the binding affinity of the targeted antibody used.
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5.3.3. Cell binding assay.

Cell binding analysis, which has been used previously for evaluating the affinity of various
kinds of targeting antibodies or ligands, was also studied here to verify the results from SPR
experiments. Anti-MUC1 was selected as the model antibody. A459 cell line, homo sapiens lung
carcinoma, which can produce MUC1 fibers was selected as the cell culture model. Another
targeting reagent, Anti-NMDAR1 antibody (anti-NR1), which targets neurons, was also studied.
For targeting by anti-NR1, neuroblastoma cells were used as the cell culture model.

For this cell binding assay, sets of rhodamine-labeled liposomes with various the appropriate
targeting or control antibody surface densities were prepared. Rhodamine C18 was incorporated
into the lipid bilayer of the liposomes during the synthesis. Confluent cells were treated with
liposome samples of various dilutions, incubated for 6 hours, and then washed with a buffer to
remove the non-specific bound liposomes[178]. In some other studies, the fluorescence from the
rhodamine-labeled liposomes was just viewed under microscope to prove the targeting efficacy,
but in this study the cells was measured by plate reader to determine the amount of the liposomes
bound to cells (Figure 18a &b). As shown in this figure, the amount of liposome binding after
incubation was found to increase initially with the increase of the surface density of the targeting
antibody, reaching the saturation when the surface density reached the value similar to that found
in SPR experiments.
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To quantitatively investigate the saturation phenomenon for both targeting antibodies, a
method was introduced to quantify the improvement of binding efficiency, by comparing the area
under each curve. The targeting index (TI) was defined as the area under the sample curve
divided by the area under the control curve produced by the liposomes with non-targeting
antibody[192]. This method was originally designed to evaluate the association strength and the
washing efficacy in ELISA. The TI as a function of the surface density of the targeting antibody
is shown in Figure 18c. Both curves demonstrated saturation behavior with the threshold antibody
surface density of approximately 1.6×108 antibody/mm2, in good agreement with the data
obtained in the SPR experiments.
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Figure 18. Cell binding assay. Plot of fluorescent intensity from immobilized liposomes
as the function of dilution times. Anti-MUC1 antibody (a) and Anti-NR1 (b). The
comparison of target index of anti-MUC1 and anti-NR1 as the function of antibody
surface density (c).
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These results showed a good correlation between SPR and cell binding experiments.
However, compared to a traditional cell binding assay, SPR approach enjoys several advantages.
First, SPR analysis is more focused on the real targeting mechanisms, excluding other factors
including the property of the delivery vehicles or cells. For example, polymeric NPs and other
widely used nano-sized vehicles cannot be taken up or merged with cells as quickly as liposomes,
so their actual targeting efficacy derived from the targeting reagents could be difficult to compare.
Second, SPR provides more quantitative measurement and allows one to determine the value of
the association constant, increasing the reliability of the experiments. In addition, SPR is a
real-time analysis, offering kinetic measurements of both the association rate and dissociation rate.
This facilitates the exploration of the in-depth mechanism of binding affinity. The indication in
this study that the primary contributor to the avidity effect is the reduced dissociation rate serves
as a good example of the advantages of studying the kinetic process. Finally, compared to cell
binding analysis, SPR requires a smaller amount of sample for analysis and is a label-free
experiment, which could be beneficial in those cases when there is a concern that the properties of
the labeled vectors could be different from the properties of the unlabeled vectors.
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5.4. Conclusion
The increase of targeting efficacy as the increase of surface density of the targeting antibody
derived from the avidity effect reached a plateau at a certain surface density of the targeting
antibody. We developed a method to determine the threshold surface density, and this density was
found to be consistent regardless of the size and even the type of the targeting antibody. This
threshold is believed essential in the design of optimized drug delivery vehicles. Moreover, the
developed SPR based methodology can be applied universally to many different delivery systems.
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CHAPTER 6
IN VITRO EVALUATION OF THE PROTECTIVE EFFICACY OF
SIMULTANEOUSLY DELIVERED ANTIOXIDANT AND GLUCOCORTICOID
DRUGS
6.1. Introduction
COPD, the third leading cause of death in the US according to a recent WHO report,
includes inflammatory conditions such as chronic bronchitis, emphysema, and airway obstruction,
with cigarette smoking being the primary cause [193-195]. Non-smoking COPD is believed to be
related to air pollution, including ambient, traffic-related, or indoor air pollution [196, 197].

Currently, this disease has no practical cure, and most of the available treatments are limited to
relieving the symptoms and/or slowing its progress [198], and even these, especially the latter, have
been found to have limited effectiveness [144, 199].

Similar to most inflammatory diseases, oxidative stress, the central feature of COPD, is
considered to be both the initiator and the primary driving force [200]. Given its function, the
large surface area and the associated blood supply, the lung is particularly vulnerable to damage
from this stress [201]. In the case of COPD, exogenous oxidative stress from cigarette smoke
(mainly from the solid phase after combustion) or other air pollutants has been found to be the main
factor in the disease’s pathogenesis [202]. This stress leads to a progressive and irreversible loss of
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airflow in the lung, an inflammatory response that is resistant, or insensitive, to the glucocorticoid
therapy [144, 145], a treatment protocol generally accepted to be effective in the suppression of
other inflammatory conditions. Used to treat several inflammatory illnesses [199], glucocorticoids
were first widely prescribed in the treatment of the rheumatoid arthritis [203, 204], and then later
generalized to other inflammatory situations, for example those affecting the pulmonary and
ophthalmic systems [205-207].

Many mechanisms attribute to the anti-inflammatory effect of glucocorticoids, including
those responsible for the suppression of pro-inflammatory genes and for the activation of
anti-inflammatory ones [208] [209], and the former one was considered as the principle mechanism.
Glucocorticoids bind to glucocorticoid receptors (GR) forming an activated GR complex and
migrate to the cytoplasm, recruiting the transcriptional co-repressor histone deacetylase-2 (HDAC2)
which has the ability is to switch off the many activated inflammatory genes that encode cytokines,
chemokines, adhesion molecules, and inflammatory enzymes [27, 209].

In general, HDAC is able is to remove acetyl moieties from histones, resulting in the
condensation of the chromatin structure around the histone cores preventing their transcription
[210], meaning it can silences the genes. HDAC2 is one of the 18 isoforms in the HDAC family
that has been hypothesized to play a central role in the transcription of genes associated with
NF-kappaB and other pro-inflammatory factors [211-213]. On the other hand, histone acetylation
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by histone acetyltransferases (HATs) disrupts the attractive electrostatic interaction between the
DNA and the histone, resulting in the unwrapping of the DNA. The balance between HDAC2 and
HAT is crucial for pro-inflammatory gene expression. Previous studies have shown that the high
oxidative stress inhibits both the activity and the production of HDAC2 and in COPD patients,
thus enhancing gene expression of pro-inflammatory factors [214, 215] (Figure 19).

Figure 19. Glucocorticoid suppression of activated inflammatory genes. Inflammatory
stimulus activates the inhibitor of nuclear factor kappa B kinase, which therefore
activates NF-kappa B. A dimer of p50 and p65 NF-kappa B proteins translocates to the
nucleus and binds to specific kappa B recognition sites on the promoter regions of
inflammatory genes and to co-activators such as the cyclic AMP response element
binding protein (CBP). The co-activator causes acetylation of core histones, activating
gene expression of inflammatory proteins. Activated glucocorticoid receptors (GRs)
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bind to coactivators in the nucleus to inhibit histone acetyltransferase (HAT) activity
directly. GRs also recruit histone deacetylase 2 (HDAC2), leading to the suppression of
the activated inflammatory genes.

The idea of restoring the production and activity of HDAC2 by introducing antioxidants
have been proven by using polyphenols [200], Nrf2 activator [216], and enzyme mimetics. Thus,
we hypothesize the co-delivery of glucocorticoids with antioxidants can restore the
anti-inflammatory efficacy of glucocorticoids. In addition, since in the case of COPD, oxidative
stress is not only the primary driving force of the inflammatory response but also one of the initial
factors, antioxidants are also considered as potential therapeutic agents for COPD itself. However,
limited studies have focused on the co-delivery of both antioxidants and glucocorticoids to create a
synergistic effect [217, 218]. To address this need, the study reported here used nano-sized
liposomes to deliver both antioxidants and glucocorticoids to the lungs to improve the treatment of
COPD.

Recently, such nano-carrier systems have received increasing attention in pulmonary drug
delivery especially for local lung diseases. The application of nano-carriers in lung offers several
advantages including 1) the potential to achieve relatively uniform distribution of a drug dose
among the alveoli; 2) enhanced solubility of the DEX than its aqueous solubility (glucocorticoids);
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3) the sustained release of a drug which consequently reduces the dosing frequency; 4) the
suitability for delivery of macromolecules (SOD enzyme); 5) a decreased incidence of side effects;
6) improved patient compliance; 7) the potential of drug internalization by cells; and 8) increased
stability. [219].

Liposomes, colloidal dispersions with self-assembling structures due to the intrinsic
interfacial chemistry of phospholipids, enjoy additional advantages for pulmonary administration
over other nano-sized carriers and polymeric nanoparticles. Most importantly, liposomes, which
are able to encapsulate hydrophilic, hydrophobic, or amphiphilic substances in either the core or the
bilayer membrane without molecular modification, have a high drug loading capacity [220].

Like most nano-medicines for pulmonary delivery, in earlier studies, liposomes were
designed to be administrated by nebulizer [221]. However, because of their high surface energy,
the disturbance during nebulization can cause agglomeration in the colloidal dispersions. Moreover,
the chemical stability of colloidal dispersions is another problem due to the hydrolysis and
degradation of both the liposomes and drugs [222]. Therefore, in recent studies, liposomes were
designed to be freeze-dried for storage, and later the micron-sized powder of the aggregation of
nano-sized particles would be administrated by DPIs [223, 224].
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6.2. Materials and Methods
6.2.1. Materials

The lipopolysaccharide (LPS) was purchased from ENZO Life Science as were an A549
Homo sapiens lung carcinoma cell and RAW 264.7, while a mouse leukaemic monocyte
macrophage cell line was purchased from ATCC. Dulbecco’s Modified Eagle Medium (DMEM),
Hank’s Balanced Salt Solution (HBSS), Phosphate Buffered Saline (PBS), Fetal Bovine Serum
(FBS), Trypsin EDTA 1X in HBSS, and Antibiotic/Antimycotic (anti/anti) solution were purchased
from Cellgro Mediatech, Inc. An E.Z.N.A Total RNA kit was purchased from Omega Bio-Tek, Inc.,
and a PerfeCTa SYBR Green FastMix PCR Kit and a qScript cDNA SuperMiX were purchased
from Quanta Biosciences, Inc. Primers for the targeting and housekeeping genes were purchased
from Integrated DNA Technologies, Inc. DNAse, RNAse and Protease free water were purchased
from Acros Organics. Human interleukin 8 (IL-8) ELISA MAX Deluxe was purchased from
BioLegend, Inc., and MTT Cell Proliferation Assay from ATCC. All other chemicals were
purchased from Sigma-Aldrich and used as received unless otherwise specified.

6.2.2. Cell Culture Models

Cell cultures of both A549 and RAW 264.7 were passaged in non-surface treatment T75 flasks
with filter caps. These cultures were subsequently maintained using DMEM with 10% FBS (heat
inactivated) and a 1% anti/anti solution. This mixed medium was further filtered through a 0.2 μm
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vacuum filtration systems. When the amplification of the cells reached approximately 90%
confluence, they were collected for the next passage. After proliferation, cells were seeded onto 24
or 48 well-plates at a concentration of 104-105 cells per mL one day before the experiments. A 0.25%
trypsin solution was used to remove the cells from the surface of the flasks between generations.
All cell lines were maintained in a continuous culture at 37 °C and 5% CO2 in an incubator.

For the A549 and RAW 264.7 co-culture, cells were collected and mixed at a 5:1(A549: RAW
264.7) ratio and later seeded on well-plates.

6.2.3. Cell Treatment

LPS was dissolved in the mixed DMEM medium, the resulting concentrations selected to
induce a significant but submaximal release of IL-8 and other inflammatory signals. Initial
experiments were conducted to obtain a concentration response curve of effect of the LPS (1-1000
ng/mL) on the release of IL-8. According to previous research, A549, a type of carcinoma cell,
exhibits increased tolerance for abnormal situations, and thus, the effective challenging
concentration of LPS should be higher for it than for other primary cells [225]. H2O2 was used in
the subsequent experiments to mimetic the oxidative stress in the lungs of COPD patients. Similar
to the LPS, an initial experiment was also conducted to determine the appropriate H2O2
concentration for inducing enough oxidative stress to introduce glucocorticoid repression in
conjunction with the LPS challenge but only a limited inflammatory response [226].
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Protective drugs, glucocorticoids and antioxidants, were also dissolved in the DMEM medium
mixture. A 20 ug/mL DEX stock solution was prepared by dissolving 1mg DEX in 1 mL absolute
ethanol and diluting it to create a 50 mL medium mixture. For the drug treatment experiment, the
cells cultured in the well plates were incubated with drugs or liposome-loaded drugs one hour
earlier than the LPS challenge or the combination of LPS and hydrogen peroxide.

Determination of the ROS Production

The ROS in cells was determined using 6-carboxy-2,7-dichlorodihydro -fluoresceindiacetate
(DCFH-DA). After entering the cells, DCHF-DA, an ester that is freely permeable across the cell
membrane, loses the diacetate group by esterase in the cells, becoming DCFH, which is not
permeable across the membrane. Here DCFH functioned as a substrate for oxidation by ROS,
producing a highly fluorescent intracellular product, DCF. For the ROS detection assay, the cells
were seeded in 96 well plates. After being treated with LPS and other challenges with or without
protection from drugs, the cells were washed twice with a medium and then incubated with
DCFH-DA (10 uM) for 30 min at 37°C in the cell culture incubator. After a washing with PBS, the
fluorescence was measured using a fluorescence microplate reader (excitation λ 495nm and
emission λ 520nm) [227]. Hydrogen peroxide was included as the positive control.

6.2.4. Released IL-8 Analysis by ELISA

IL-8, a pro-inflammatory mediator, was used as the index of the inflammatory level. In this
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study, the amount of IL-8 released was measured using a commercially available enzyme-linked
immunosorbent assay (ELISA). The supernatants of the cell culture experiments were collected,
diluted, and assayed according to the manufacturer’s protocol. The optical density (OD) at 450nm
was measured using a microplate reader. The relationship between the OD at 450nm and the IL-8
concentration was obtained by adding the standard samples from the serial dilution of the LPS
solution with a known concentration to the assay. The final concentrations of each sample were
calculated as the means of the results from the sample dilution yielding ODs in the linear region of
the calibration curves.

6.2.5. Gene Expression Measured Through Quantitative PCR

To further investigate the protective effect of the glucocorticoids and the ability of
antioxidants to restore their function, quantitative PCR was used to analyze the detailed alterations
in the gene expression, beginning with the extraction of the RNA from the in vitro experiments and
its purification. This extraction of all RNA from the cell lysates was achieved by using the EZNA
total RNA kit according to the manufacturer’s protocol. After the tripsiniztion and homogenization
of the cells in a lysis buffer, the samples were translated to a HiBing RNA column with a selective
membrane, which uniquely retains the RNA while washing buffers remove the proteins. The RNA
was subsequently eluted from the column by adding DEPC-treated water. The amount of RNA was
measured using the absorbance of its solution at 260nm, and the ratio of absorbance at 260nm over
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280nm was measured and found to be in the range of 1.98-2, indicating a pure RNA solution.

After the RNA extraction, a reverse transcription reaction was conducted using qScript XLT
cDNA SuperMix. Based on the protocol, test tubes containing a mixture of the extracted RNA and
superMix were incubated at 25 °C for 5 minutes, followed by 60 minutes of incubation at 42 °C,
and finally, the test tubes were held at 85 °C for another 5 minutes in a Rotor-Gene 3000 Thermal
Cycler (Corbet Research, Quiagen Inc.).

Quantitative PCR analysis was conducted using a PerfeCTa SYBR Green FastMix PCR Kit
based on the manufacturer’s instructions, also in the Rotor-Gene 3000 Thermal Cycler. The cDNA,
SYBR Green FastMix PCR Kit and the primer mixtures, their composition described below, were
initially denatured at 95°C for 15 min. Amplification was then conducted using the following
thermal cycling: 94°C for 20 sec, 60°C for 20 sec and 72°C for 15 sec, all with 45 cycles. Finally,
melt curves were obtained by increasing the temperature from 25°C to 85°C.

Primers were designed as follows (annealing temperature and product size appear in
parentheses): IL-8 sense 5' - ACT GAG AGT GAT TGA GAG TGG AC -3' and antisense 5' - AAC
CCT CTG CAC CCA GTT TTC -3'; NF kappa B sense 5' - ATG TAT GTG AAG GCC CAT CC -3'
and antisense 5' - TTG CTG GTC CCA CAT AGT TG -3'; HDAC2 sense 5' - CCC TGA ATT TGA
CAG TCT CAC C -3' and antisense 5' - CAC AAT AAA ACT TGC CCA GAA AAA -3'; the
housekeeping gene GAPDH sense 5' - TCA AGG CTG AGA ACG GGA AG -3' and antisense 5' 135

ATG GTG GTG AAG ACG CCA G -3' [228]. The threshold level was set sufficiently above the
background noise. The CT value for each sample fluorescence curve was determined at the point
where the fluorescence curve crossed the threshold line. For this experiment, 0.02 was selected as
the threshold. In a preliminary experiment, the efficiency of the targeting and housekeeping gene
primers was calculated from the CT values of the serially diluted cDNA solution with known
concentrations, with 100% efficiency indicating a doubling of the amount of the amplified
sequence in each PCR cycle.

Quantitative analysis of gene expression was calculated based on the Ct from a targeting gene
(A) and a housekeeping gene (B) for the two cell types, untreated cells and sample cells. Thus, the
relative gene expression was represented by this formula:
⁄N

N

−∆∆C = C

,

,

−C

,

=2

,

∆∆

− C

,

,
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,

,

where Nsample and Nuntreated represent the number of targeting genes copies in the untreated and
samples cells, respectively, and CT, untreated, A, CT, treated, B, CT, sample, A, and CT, sample, B , the average CT
values calculated from three PCR replicates for both the targeting gene (A) and the housekeeping
gene (B). This approach allows the gene amount from the samples with various cell amounts to be
normalized by the housekeeping gene.
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6.2.6. Statistical Analysis

The values of the protein amount obtained from ELISA, the ROS amount obtained from the
DCFDA assay, and the gene expression determined from quantitative PCR were compared using
the t-test. The number of replicates was n>3.

6.3. Results and Discussion
6.3.1. LPS Challenge on A549 Cells

LPS, also known as endotoxin, is a large molecule composed of a covalently bonded lipid and
polysaccharide found in the outer membrane of gram-negative bacteria. It has been frequently
applied to induce inflammatory responses in many cell types in in vitro experiments [229]. In this
study, LPS was used as the main stimulator of inflammatory response.

IL-8 is one of the chemokines produced by many types of cells including epithelial cells, the
main function of which is to attract granulocytes. Thus, IL-8 has been applied to evaluate the level
of inflammatory reaction in both in vitro and in vivo experiments. Here, commercially available
direct sandwich ELISA conducted in 96 well plates was used to determine the inflammatory level
after LPS activation.

The concentration of the released IL-8 in the medium from A549 cells was plotted against the
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various concentrations of the LPS used at 12 hrs time point in Figure 20A. The results suggested
that the released concentration of IL-8 was positively related to the concentration of LPS used,
reaching a maximum at approximately 1000 μg/mL. Further increased LPS concentration induced
obvious cell apoptosis (not shown in the figure). Here 100μg/mL and 10 μg/mL (853±120 and 720
±66 pg/mL) were selected for further investigation because the released IL-8 was significantly
higher than the baseline (312±34 pg/mL, P<0.001) but did not reach the peak secretion. In
comparison, this concentration was much higher than that used in most studies using primer cells
(500 ~ 10 ng/mL) [230], but was consistent with those using A549 cells [226].
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Figure 20. DEX reduces the inflammatory response in A495 cells stimulated by the LPS
challenge. (a) Concentration-dependent effect of the challenged LPS on IL-8 release in
A549 cells over a period of 12 hrs. (b) The concentration- dependent effect of
dexamethasone on LPS challenged cells in 12 hrs. (c) ROS production from the LPS
challenged A549 cells.
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With the appropriate concentration of LPS (10 μg/mL) as the challenge, an initial DEX
protective experiment was conducted. Previous studies found that the presence of LPS leads to an
elevation of the ROS level in A549 cells, perhaps inducing glucocorticoid resistance [231].
However, as shown in Figure 20B, the IL-8 production was effectively suppressed to the baseline
level by even a low concentration of DEX (0.001 uM, 351±30 pg/mL in comparison to a positive
control 873±100 pg/mL, P<0.001), which is the lowest practical concentration used in previous in
vitro experiments [226]. Thus, no obvious glucocorticoid resistance was observed from the LPS
challenge alone. The results of the DCFH-DA assay analyzing the ROS generation in A549 with
LPS can be seen in Figure 20C. Unlike as found in several previous studies, the serial
concentrations of LPS did not induce any relative change in the fluorescent intensity from the DCF,
and the fluorescent intensity of the cells treated with the highest concentration of LPS (100 ug/mL)
was not significantly higher than the negative control. In addition, the combination of LPS and
DEX also did not result in an increase in fluorescence. Here 100 μM H2O2 was included as positive
control based on the standard protocol.

This inconsistency of the ROS production may be a result of the incubation environment and
the time of cell collection. Although in the process of inflammatory response, both epithelial cells
and macrophages can produce ROS, the alveolar macrophages have been found to produce most of
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the increased amount of ROS, including oxygen free radicals and hydrogen peroxide [232, 233]

6.3.2. Co-culture of A549 and Macrophages

Macrophages are recognized as the primary source of ROS in inflammatory response.
Activated macrophages produce oxygen free radicals through the activation of nicotinamide
adenine dinucleotide phosphate reduced (NADPH) oxidase, which is a complex enzyme system
present in phagocytes.

Fluorescent Intensity (OD)

12000

A

LPS
LPS+DEX
Negative Control

10000
8000
6000
4000
2000
0

Control

10 g/mL

1 g/mL

LPS concentration

141

0.1 g/mL

Released IL-8 (pg/mL)

1200

B

16 hrs
8 hrs
DEX ++: 0.1 M
DEX +: 0.01 M

1000
800

LPS +++: 100 g/mL
LPS ++: 10 g/mL
LPS +: 1 g/mL

600
400
200
0
LPS
DEX

+++

++

+

+++
++

++
++

+++
+

++
+

Figure 21. Addition of RAW 264.7 macrophages into the in vitro model. (a)
Concentration dependent effect of LPS induced ROS production in RAW 264.7
macrophages (0.001 μM of DEX). (b) LPS treated A549 and RAW 264.7 cell co-culture.
A549 and RAW 264.7 were seeded on wells at a ratio of 5:1. Two time points were
included.

We used a co-culture of A549 and RAW 264.7 macrophages, a combination developed to
mimetic pulmonary tissue composition in previous studies [234]. A preliminary test was conducted
to evaluate the ROS production via a DCF assay. Figure 21A showed a significant increase in the
ROS production after the treatment of LPS (9458 ±1520 versus 2045 ± 367 of negative with
P<0.01). In addition, as the LPS concentration increased, the ROS production also increased (9458
±1520 from 10 μM versus 4239 ±567 from 0.1 μM). This proved that, the AW 264.7 macrophages
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can produce ROS by the challenge of LPS.

However, as shown in this figure, the addition of DEX (0.1 uM) effectively reduced the
production of ROS (9458 ±1520 versus 3624 ± 1235 P<0.01), and the reduced ROS concentration
was not significantly different from the baseline control of non-treated cells, indicating that the
ROS produced from RAW 263.7 may not be enough to generate glucocorticoid resistance.

To investigate that if the ROS produced from RAW 264.7 was enough to generate
glucocorticoid, a co-culture system with both RAW 264.7 and A549 cells was used. Similar to
previous studies, cells were amplified in flasks separately, and subsequently, the two harvested cell
suspensions were mixed at a 5:1 (A549: RAW 264.7) ratio, before seeded on well-plates. As
illustrated in Figure 21B, the co-culture system was more sensitive to stimulation from LPS, a
higher concentration of IL-8 being observed after an incubation period of 12 hours, because
macrophages play an essential role in the amplification of inflammatory responses by producing
many types of cytokines, including IL-8. However, as shown in the figure, the addition of DEX also
results in the reduce of the IL-8 levels, especially for short-term incubation. More specifically, even
the lowest practical DEX concentration (0.01 μM) can significantly reduce the amount of IL-8
released at both the 12 and 6 hour time point.

Based on the results from both the DCF-DA assay and the IL-8 ELISA, endogenous ROS from
the co-culture of A549 and RAW 264.7 was found to be not enough to induce obvious
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glucocorticoid resistance, and, therefore, exogenous ROS appears to be necessary to establish a
model to evaluate the synergistic effect of both antioxidant and glucocorticoid drugs.

6.3.3. Exogenous ROS-Induced Glucocorticoid Resistance

Hydrogen peroxide, one kind of ROS, plays a pivotal role in inflammatory response. Many
enzymes and reactions relate to hydrogen peroxide, for example glutathione peroxidase,
superoxide dismutase, catalase, and Fenton chemistry. For this reason, hydrogen peroxide has been
considered as a potential reagent for introducing oxidative stress in in vitro experiments. Previous
studies have found that hydrogen peroxide at an appropriate concentration alone does not incease
the inflammatory response but is enough to generate glucocorticoid resistance. Here the
concentration dependent glucocorticoid resistance from hydrogen peroxide was analyzed by
determining the concentration of the IL-8 released in Figure 22. As the figure shown, the low
concentration of hydrogen peroxide (10 μM) did not induce an inflammatory response or block the
function of DEX. On the other hand, a high concentration of hydrogen peroxide (1000 μM) induced
a significant increase in the release of IL-8 (1011±43 pg/mL), and an even higher concentration
caused significant cell death (not shown in the figure). For this study, hydrogen peroxide with 100
μM in concentration, which effectively impacted the function of the DEX but did not increase the
inflammatory response, was selected for further investigation.
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Figure 22. Hydrogen peroxide was applied as exogenous oxidative stress. The
concentration dependent glucocorticoid resistance effect on A549cells.

6.3.4. Antioxidants Restoration of e the Function of Dexamethasone.

Many antioxidants have been claimed effective to restore the function of glucocorticoids,
including polyphenols, spin traps, and cysteine alternatives, indicating their potential as improved
therapeutic agents for glucocorticoid-resistant COPD.
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Figure 23. Effect of SOD and SOD mimetic on LPS and hydrogen peroxide stimulated
A549 cells. Cells were first incubated with DEX and SOD/SOD mimetic and later
challenged with LPS and hydrogen.

This study used SOD and SOD mimetic as antioxidants to restore the function of
glucocorticoids. To investigate their performance, it used the COPD model with a combination of
LPS and hydrogen peroxide. As shown in Figure 23, DEX alone did not recover the concentration
of released IL-8, but the addition of SOD or SOD mimetic at a high concentration (1KU/mL)
restored its level to the baseline. As the decrease of the activity of SOD and SOD mimetic used,
their function also diminished, and the level of the IL-8 released increased. In addition, as clearly
demonstrated, with the same activity, the SOD mimetic exhibited a much better protective effect
than SOD, for example at 1 kU/mL 307.5 ±43.8 pg/mL versus 436.4 ±31.5 pg/mL with p<0.01, and
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at 100 u/mL 311.3 ±30.8 pg/mg versus 658.6 ±12.2 pg/mL with p<0.001.

To explore detailed response of the cell by the challenge of LPS and hydrogen peroxide and
the treatment of the DEX and antioxidants, the change of gene expression of several biomarkers
was determined via quantitative PCR. In the mechanism of glucocorticoid resistance, oxidative
stress reduces the expression of HDAC2, thus blocking the anti-inflammatory efficiency of DEX,
and LPS stimulates inflammatory response via NF-kappa B. Therefore, besides IL-8, the gene
expression of HDAC2 and NF-kappa B were analyzed (Figure 24). As Figure 24A shown, the
expression of the IL-8 gene was quite consistent with the its released concentration determined by
ELISA. Similarly, the single drug of DEX did not restore the IL-8 gene expression to its normal
level (3.51±0.23 folds of the IL-8 baseline) , while the addition of SOD and SOD mimetic
significantly reduced the IL-8 gene expression (1.50±0.06 and 1.95±0.11 folds of 1 kU/mL SOD
and SOD mimetic respectively). Similar to the IL-8 ELISA result, the protective effect of
SOD/SOD mimetic at lower concentrations was diminished, especially for the SOD enzyme.

NF-kappa B can be stimulated by such exogenous stimulators, such as LPS, TNF-alpha, and
environmental ROS to facilitate the transcription of inflammatory genes. With stimulation by LPS,
its gene expression was raised to more than 2 folds, as seen in Figure 24B. The introduction of
hydrogen peroxide and the addition of DEX did not change the expression of NF-kappa B. The
addition of hydrogen peroxide and antioxidants did not significantly change its gene expression
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level, indicating that the addition of hydrogen peroxide did not lead to the increase of
inflammatory response, but just blocked the function of glucocorticoids.

In addition, results from the gene expression of HDAC2 demonstrated that even challenged by
a high concentration of LPS, the production of HDAC remained at the normal baseline level
(0.90±0.13 fold) as seen in Figure 24C. However, the introduction of hydrogen peroxide
significantly reduced its expression level (0.54±0.04 fold), and the addition of DEX did not
recover this decrease. Once a high concentration of antioxidants was introduced, especially SOD
mimetic, HDAC2 expression was restored to normal level (0.89±0.10). The gene expression of
HDAC2 also showed that the effect of SOD mimetic was much better than that of the SOD
enzyme.

In conclusion, these results further support that oxidative stress is the primary cause of the
reduction of HDAC2 expression and the subsequent glucocorticoid resistance. In addition, the
antioxidant used here effectively restored the level of HDAC2. In contrast, most previous studies
just focused on the recovery of DHAC2 production and its activity. However, this study not only
suggested that a high concentration of potential antioxidant (SOD and SOD mimetic) can recover
the HDAC2 gene expression but also demonstrated that this recovery of the function of HDAC2
restored the anti-inflammatory effect of DEX. This result confirms the hypothesis of the
co-delivery of antioxidant and glucocorticoid drugs.
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Moreover, it is known that SOD and SOD mimetic exhibit similar active units per mg
(approximately 6000 U/mg), while the cytotoxicity of SOD mimetic is much lower than the SOD
enzyme. In addition, SOD mimetic offers other advantages over the SOD enzyme, including a
lower immunological response and more stability. Thus, this study used the SOD mimetic for
further co-delivery experiments.
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6.3.5. Liposomes Loaded Antioxidants and Glucocorticoids

The approach to load both DEX and antioxidant onto liposomes simultaneously was
illustrated in the Aim 1. In the preparation, the ratio between those two drugs was adjusted based on
the results obtained in Figure 23(1KU of SOD mimetic for 0.1 uM of DEX).

The anti-inflammatory effect of the drug-loaded liposomes was analyzed using the same
inflammatory model of A549 cells challenged by both LPS and hydrogen peroxide. Both the
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concentrations of the IL-8 released (421±78 pg/mL) and the IL-8 gene expressions (1.12±0.12
folds) of the drug-loaded liposomes were similar to the free drug mix (Figure 25a &b). The
drug-loaded liposomes exhibited a much better effect on the recovery of the HDAC2 gene
expression compared with the free drugs mixture (0.87±0.06 versus 1.13±0.08 with P<0.01).
Similar to the free drug mix, drug-loaded liposomes did not influence the gene expression of
NF-kappa B. Plain liposomes, which were included as a control to eliminate the influence from the
nano-sized vehicle.
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Figure 25. Comparison of free drug and liposome-loaded drugs. The plain liposomes
were included as a control. (A) IL-8 released from A549 cells after LPS and H2O2
stimulation. IL-8, DHAC2, and NF-kappaB gene expression are also illustrated (B, C,
and D).

The improvement of the protective effect of the drug-loaded liposomes was not demonstrated
in this static in vitro model. There was no significant improvement of drug-loaded liposomes
compared with free drug mixture. In a real situation, the clearance in the pulmonary system is
strong, and liposomes will facilitate the cellular uptaken of drugs.

To investigate the advantage of the liposome-loaded drugs, the model was modified by a
pre-incubation with drugs for 2 hrs and followed by several washing steps using HBSS buffer to
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remove the drugs not internalized by cells. Then, the cells were challenged by LPS and hydrogen
peroxide. The level of released IL-8 was analyzed by IL-8 ELISA (Figure 26). As can be seen, the
anti-inflammatory effect of the free drugs was compromised compared with the previous model
(from ~90% recovery of IL-8 to ~50%) Meanwhile, the drugs loaded on the liposomes exhibited a
much better effect in reducing the amount of released IL-8 compared with the free drugs (630±45
pg/mL versus 302±69 pg/mL with P< 0.01). This result indicates that as a delivery vehicle,
liposomes improved the cell-availability and increased the amount of internalized drugs in short
term.
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Figure 26. The IL-8 released from cells at 8 hours after the LPS and H2O2 challenge.
Drugs or liposome-loaded drugs were incubated with cells for 2 hrs and washed before
the challenge.
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Drug-loaded liposomes modified with the targeting antibody were also included in the assay
of the amount of released IL-8. The results from Aim 2 suggested that the introduction of the
targeting antibody (anti-muc1 antibody) should lead to the specific binding of the liposomes to
epithelial cells, including A549, thus further facilitating the internalization of the liposomes.
However, as shown in Figure 26, in this unique static in vitro model, the improvement of
antibody-modified liposomes was not apparent.

6.4. Conclusion
With the model consisting of the A549 cells challenged with LPS and hydrogen peroxide, the
antioxidant, SOD mimetic not only restored the expression level of DHAC2, just as most studies
have found, but also removed the glucocorticoid resistance. Liposomes loaded with both the SOD
mimetic and DEX can effectively reduce the inflammatory level, returning it back to normal.
Furthermore, liposomes increased the bio-availability of the drugs and increased the possibility of
internalization by the cells, further improving the protective effect. These results concerning the
implementation of a co-delivery liposome delivery system open new possibilities in the treatment
of COPD.
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CHAPTER 7
CONCLUSIONS AND FUTURE RECOMMENDATIONS
7.1. Conclusion
Overall, the design of the co-delivery of glucocorticoid and antioxidants in one nano-sized
targeted delivery system to treat inflammation resulting from COPD was successful in our in vitro
experiments., and this study addressed its three goals for the development of an effective drug
delivery system. First, targeted drug delivery devices carrying both antioxidant (SOD/SOD
mimetic) and glucocorticoid (DEX) drugs were prepared and characterized. Second, the effect of
the density of the targeting antibody on the affinity of nanoscale drug carriers was investigated, and
the optimal antibody density was determined. Finally, the synergistic effect between the
glucocorticoid and antioxidant drugs was evaluated using the A549 cell culture model.

The first goal was based on previous observations in the nano-carrier literature. First,
according to previous experiments, several kinds of nano-carriers with drugs were prepared and
characterized. Their size and zeta-potential were analyzed, theresults showing that they were all in
the appropriate size range of nanometer, and with an absolute value of zeta-potential to ensure their
stability as colloidal suspensions.

Second, relatively high loading capacities of all three kinds of therapeutic molecules
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(dexamethasone, SOD, and SOD mimetic) were achieved with liposomes compared to alternative
nano-carriers. To deliver the same dose of a therapeutic molecule required, a relatively lower dose
of nano-carrier if the loading capacity was high, reducing the toxicity from the carrier itself. In
addition, a high loading capacity offered the space needed for the manipulation required to load
both drugs simultaneously. For this manipulation, the ideal molecular ratio between the
glucocorticoid and antioxidant, would guide the preparation of the nano-carriers. However, the
liposomes used here exhibited the capability for loading all three kinds of therapeutic molecules,
suggesting the potential of the development of liposomes loading both glucocorticoids and
antioxidant.

The stability of the nano-carrier candidates was analyzed through the process of lyophilization
and the long-term storage. Polysaccharides, cryoprotectants, were added to prevent the aggregation
of nano-carriers during the lyophilization, with the results indicating that liposomes demonstrated
much less aggregation. Size is one of the most crucial advantages of nano-carriers as drug delivery
vehicles. Meanwhile, the liposomes with the cryoprotector retained most of the original SOD
activity, indicating that structure remained intact through lyophilization and reconstitution.
Subsequently, an accelerated aging experiment was conducted, indicating the enhanced ability of
liposomes to retain their SOD activity during the long-term room temperature storage compared
with other candidates. Thus, based on the loading capacity and the stability, liposomes were
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selected for preparing the co-delivery system. Lyophilization was required because of the
instability of the colloidal suspension and their application in the dry powder inhaler (DPI).
Because of the degradation of drugs and liposomes in the aqueous phase and the inconvenience of a
nebulizer, currently DPI is the preferred device of application.

The release profile of the glucocorticoid was analyzed using albumin as a transport vehicle for
the drug, mimicking the physiological situation of the body. Unlike for water soluble molecules,
the transportation of hydrophobic drugs, for example hormones, is facilitated by proteins such as
albumin. Unlike free drugs, dexamethasone loaded in liposomes achieved a sustained release over
the initial 4-5 days, reducing the frequency of drug administration.

The pilot co-delivery liposome system was prepared to verify the feasibility of loading two
kinds of therapeutic molecules by separate mechanisms. Both SOD/DEX and SOD mimetic/DEX
liposomes were prepared pursuing the highest loading capacity. There was neither significant
decrease of final loading capacity nor the change of physical characteristics, indicating the
liposome system was a suitable delivery vehicle in this study and ready for further investigation.

The optimized surface density of the targeting antibody was determined through the modified
surface plasmon resonance (SPR) analysis. First, unlike the normal application of SPR, the antigen
molecules were immobilized on a sensor chip, while the targeting antibody was running in the
channel along with the running buffer. A sensor chip with a high surface density of antigen
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molecules was selected to mimic the actual situation in the body.

Then, a secondary antibody was applied as a polite model in the investigation of the influence
of antibody amount and of the particle size. Avidity effect was known to raise the binding affinity
(targeting efficacy) of liposomes with multiple targeting antibodies, and the targeting efficacy
increased with an increase in the amount of targeting antibody. However, this trend saturates at a
certain surface density of the targeting antibody. This saturation point was demonstrated and
determined by the SPR experiments. Further experiments showed that the saturation point relied on
the certain surface density of the targeting antibody, regardless of the size of liposomes.

With the experience gathered from the secondary antibody, the actual primary antibody,
anti-MUC1, was analyzed using a sensor chip with the immobilized fragments of mucin 1. The
antibody surface density related binding affinity demonstrated the saturation point of the targeting
efficacy, which was found to be similar the value found in the secondary antibody experiments.
This result indicated that the saturation point might be an essential property which depends only on
the nano-carrier itself. The saturation point was crucial in the optimization of the targeting efficacy,
maximizing the targeting efficacy from a limited amount of antibody.

The conventional cell binding method was also operated in this study to determine the
targeting efficacy, which verified the surface density of the saturation point. However, SPR
demonstrated several advantages compared with the conventional method. First, a detailed
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investigation of the kinetic parameters revealed that the increased binding affinity was primarily
derived from the decreased dissociation rate. Second, the reusability of the chip provided a much
easier and faster method for determining the targeting efficacy. In addition, a smaller sample
amount was required for the analysis. Last, but most important, SPR as a more quantitative method,
is optimal for the comparison between samples.

In vitro models were able to demonstrate the synergistic effect derived from the co-delivery of
glucocorticoid and antioxidant. First, the model was developed not only by stimulating the A549
cell with lipopolysaccharide (LPS) as is done most for in vitro inflammatory model but also by
including hydrogen peroxide as an exogenous ROS. That was because that preliminary studies
showed that the endogenous ROS was not capable of generating the glucocorticoids resistance in
vitro even when A549 cells were co-cultured with macrophage cells.

The measurement of the concentration of the released Interleukin 8 as the index of the
inflammatory level was determined by the commercially available ELISA kit. As indicated by the
concentration of IL-8, the ability of DEX to reduce its level of IL-8 when stimulated by LPS was
hindered by the addition of hydrogen peroxide, a condition addressed by the addition of
antioxidants, SOD or SOD mimetic.

In addition, the gene expression of histone deacetylase-2 (HDAC2) was found to be
suppressed by increased oxidative stress, considered as the primary cause of glucocorticoid
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resistance. The addition of antioxidants restored the level of HDAC2 gene expression, while the
gene expression of NF-kappa B remained unchanged, indicating that the stimulation of the
inflammatory response was uniquely from LPS and that the addition of exogenous ROS did not
increase the stimulation but only compromised the anti-inflammatory function of the
glucocorticoids.

The liposomes loaded with both glucocorticoid and antioxidant were also included in the
analysis, which processed the optimized ratio between these two drugs. A similar protective effect
was discovered compared to the free drug mixture in this static cell culture model. To demonstrate
the advantage of liposomes, a washing step was introduced into this model to remove the drugs
neither binding to nor uptaken by the cells. Results from both the release of IL-8 concentration and
the gene expression of several factors suggested an enhanced protective effect from liposomes
compared to the free drugs mixture, revealing an increase in the cell availability of those drugs
loaded by liposomes.

In addition, the results demonstrated that SOD mimetic performed much better in this in vitro
model compared to the actual SOD with the same amount of the active unit. In consideration of
other advantages of the SOD mimetic, for example its higher stability, smaller molecular weight,
and less immunogenicity, this metalloporphyrin, was selected over SOD. This study also included
liposomes decorated with the targeting antibody, anti-muc1.
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7.2. Future Directions
While this work focused on the in vitro protective efficacy reported here, there is potential for
application in the treatment of COPD. However, much work remains to be done.

One study could involve detailed analysis of the characteristics of the liposomes-loaded drugs.
First, detailed size-distributions and shapes of liposomes could be determined by such techniques
as atomic force microscopy (AFM) or scanning electron microscope (SEM). That is important,
because the DLS applied in this study is claimed not ideal for analyzing their sizes. Furthermore,
their composition could be analyzed including the drug molecules and each lipid components, and
their distribution in the liposomes. This property is crucial for predicting the body’s response to this
therapeutic system, including its degradation and bio-distribution.

The ultimate goal for this liposome is to be delivered into the respiratory system by DPI. The
property of the freeze-dried powder is important for this application as it contains not only
aggregated liposome particles but also covered by polysaccharides, cryoprotectors, meaning the
size is larger than that of liposome. This increased size would need to be determined because it is
crucial to the nano-carriers’ deposition location in the respiratory system. Other drying techniques
could also be applied if it is necessary.

A rat model could also be used to analyze the distribution and targeting efficacy of liposomes.
First,a nasal drop administration could be applied to evaluate the targeting efficacy of samples with
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and without the targeting antibody. Subsequently, dry powder could be administrated to
demonstrate the bio-distribution of this liposomes system.

To explore the ability of this liposomes system to effectively treat COPD, our collaborators at
the Medical University of South Carolina will develop a rat model with this condition. with rats
exposed to sidestream cigarette smoke in a cigarette smoke chamber. Then, a detailed comparison
of the rats with liposomes administration and the control group will be conducted, primarily
focused on the harvested lung tissue. If the rat study is successful and indicates an improvements in
the anti-inflammatory functions compared with traditional DEX administration, then a small scale
human trial will be conducted.

Future work could also include the generalized application of this SPR technique. Given its
advantages compared with the conventional methods, this method may be applicable for any
targeting molecule. In addition, other types of nano-sized carriers besides liposomes could also be
analyzed using this method.
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APPENDICES
APPENDIX A: Abbreviations
BSA- Bovine serum albumin

COPD- Chronic obstructive pulmonary disease

DCF- 2',7'-dichlorodihydrofluorescein diacetate

DEX- Dexamethasone

DLS- Dynamic light scattering

DMEM- Dulbecco’s Modified Eagles Medium

DPI- Dry powder inhaler

ELISA- Enzyme-linked immunosorbent assay

FBS- Fetal bovine serum

GR- Glucocorticoid receptor

HAT- Histone acetyltransferases

HDAC2- Histone deacetylases 2

IL-8- Interleukin 8
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LPS- Lipopolysaccharide

MDI- Metered dose inhaler

MUC1- Mucin 1

NF-κB- Nuclear factor kappa-light-chain-enhancer of activated B cells

NP- Nanoparticle

PCR- Polymerase chain reaction

PLA- Polylactic acid

PLGA- Poly(lactic-co-glycolic acid)

PVA- Polyvinyl alcohol

ROS- Reactive oxygen species

SOD- Superoxide dismutase

SPR- Surface plasmon resonance
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APPENDIX B: CD spectrum
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APPENDIX figure 1. The percentage of α-helix during in 37℃ incubation up to 120
days imitating 1 year storage at room temperature. The decrease of the percentage
illustrated the structural deformation during storage.
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APPENDIX C:

The sensorgrams of liposomes with control antibody
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APPENDIX figure 2. Both sesorgrams of plain liposomes and liposomes modified with
control antibody (anti-bovine antibody) were found with no change during the injection.
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